var title_f0_15_240="Overlapping fracture";
var content_f0_15_240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Complete fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Overlapping complete fracture of radius and ulna (100 percent displaced) in a 7-year-old child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_240=[""].join("\n");
var outline_f0_15_240=null;
var title_f0_15_241="Phenylephrine: Patient drug information";
var content_f0_15_241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=see_link\">",
"       Phenylephrine (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=see_link\">",
"       Phenylephrine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=see_link\">",
"       Phenylephrine (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=see_link\">",
"       Phenylephrine (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11828 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_241=[""].join("\n");
var outline_f0_15_241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_15_242="Patient information: Total anomalous pulmonary venous connection in children (The Basics)";
var content_f0_15_242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85377\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/36/34372\">",
"         Total anomalous pulmonary venous connection",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/31/6642\">",
"         Patient information: Atrial septal defect (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/31/31218\">",
"         Patient information: Newborn appearance (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Total anomalous pulmonary venous connection in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/total-anomalous-pulmonary-venous-connection-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H257226461\">",
"      <span class=\"h1\">",
"       What is a total anomalous pulmonary venous connection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A total anomalous pulmonary venous connection is a rare condition that involves the veins that carry blood from the lungs to the heart. These veins aren&rsquo;t connected to the correct spot in the heart. Doctors call this condition &ldquo;TAPVC&rdquo; for short.",
"     </p>",
"     <p>",
"      Normally, blood flows through the heart and lungs in the following way: Blood from the body comes into the right atrium. It flows into the right ventricle and then to the lungs. In the lungs, the blood picks up oxygen. Then the blood goes into the left atrium and into the left ventricle. From there, the heart pumps the blood around the body (",
"      <a class=\"graphic graphic_figure graphicRef83996 \" href=\"UTD.htm?33/36/34372\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      In a TAPVC, blood from the lungs does not return to the left atrium. Instead, it returns to the right atrium. Or the blood returns to another vein in the body and then to the right atrium. As a result, the blood with the oxygen can&rsquo;t easily get to the organs in the body. Plus, sometimes the veins carrying the blood from the lungs get blocked. Both of these things can cause symptoms.",
"     </p>",
"     <p>",
"      There are different types of TAPVC, depending on where the veins from the lungs attach. TAPVC is a condition that children are born with. Doctors don&rsquo;t know what causes it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H257226493\">",
"      <span class=\"h1\">",
"       What are the symptoms of a TAPVC?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on the type of TAPVC and whether the veins carrying blood from the lungs are blocked.",
"     </p>",
"     <p>",
"      Babies whose condition is severe get very sick within the first 12 hours after birth. Their skin looks blue and they have a lot of trouble breathing.",
"     </p>",
"     <p>",
"      Babies whose condition is not as severe usually start having symptoms later on. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breathing faster than usual",
"       </li>",
"       <li>",
"        Not feeding well",
"       </li>",
"       <li>",
"        Not gaining weight or growing well",
"       </li>",
"       <li>",
"        Skin that looks blue",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H257226508\">",
"      <span class=\"h1\">",
"       Will my baby need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The test most often done to check for a TAPVC is an echocardiogram (also called an &ldquo;echo&rdquo;). This test uses sound waves to create a picture of the heart as it beats. It shows how blood flows through the heart and lungs.",
"     </p>",
"     <p>",
"      Sometimes, doctors do other imaging tests. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H257226523\">",
"      <span class=\"h1\">",
"       How is a TAPVC treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A TAPVC is treated with surgery. During surgery, the doctor will fix or move the veins so that blood from the lungs gets to the correct place.",
"     </p>",
"     <p>",
"      But before your child has surgery, his or her breathing and general medical condition need to be under control. If your baby&rsquo;s condition is severe, he or she might need 1 or more of the following before surgery:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Extra oxygen or other medicines",
"       </li>",
"       <li>",
"        A breathing tube &ndash; This is a tube that goes down the throat and into the lungs. The other end is attached to a machine that helps with breathing.",
"       </li>",
"       <li>",
"        A heart procedure that helps the blood with oxygen get to the left atrium",
"       </li>",
"       <li>",
"        To be on a heart and lung machine &ndash; This machine, which doctors call &ldquo;ECMO,&rdquo; takes over the jobs of the heart and lungs. It pumps blood from your baby&rsquo;s body, gives it oxygen, and pumps it back into the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H257226538\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your child&rsquo;s individual situation. All children with TAPVC need to see their heart doctor for regular follow-ups.",
"     </p>",
"     <p>",
"      Sometimes after surgery, a problem can happen with 1 of the veins. If this happens, a child might need surgery again. Also, children sometimes have heart rhythm problems after their surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H257226553\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=see_link\">",
"       Patient information: Newborn appearance (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/31/6642?source=see_link\">",
"       Patient information: Atrial septal defect (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/15/242?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85377 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-42AE1A7C96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_242=[""].join("\n");
var outline_f0_15_242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257226461\">",
"      What is a total anomalous pulmonary venous connection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257226493\">",
"      What are the symptoms of a TAPVC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257226508\">",
"      Will my baby need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257226523\">",
"      How is a TAPVC treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257226538\">",
"      What will my child&rsquo;s life be like after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257226553\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/36/34372\">",
"      Total anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/31/6642?source=related_link\">",
"      Patient information: Atrial septal defect (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=related_link\">",
"      Patient information: Newborn appearance (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_15_243="Cord hemangioma";
var content_f0_15_243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cord hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_243=[""].join("\n");
var outline_f0_15_243=null;
var title_f0_15_244="Septated cystic hygroma";
var content_f0_15_244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal view of the cystic hygroma demonstrating the presence of septations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynn Simpson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_244=[""].join("\n");
var outline_f0_15_244=null;
var title_f0_15_245="Muscle compartments of the foot";
var content_f0_15_245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Muscle compartments of the foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compartments of the foot:",
"    <ul>",
"     <li>",
"      Interosseous (turqoise) &mdash; Interosseus muscles, each in its own compartment.",
"     </li>",
"     <li>",
"      Calcaneal (pink) &mdash; Flexor digitorum brevis, quadratus plantae and adductor hallucis.",
"     </li>",
"     <li>",
"      Lateral (green) &mdash; Flexor digiti minimi and abductor digiti quinti.",
"     </li>",
"     <li>",
"      Medial (red) &mdash; Abductor hallucis and flexor hallucis brevis muscles.",
"     </li>",
"     <li>",
"      Superficial (blue) &mdash; Flexor digitorum brevis, lumbricals, flexor digitorum longus tendons.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_245=[""].join("\n");
var outline_f0_15_245=null;
var title_f0_15_246="Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis";
var content_f0_15_246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/246/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/246/contributors\">",
"     Jack JH Bleesing, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/246/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/246/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/246/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/15/246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20229218\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune lymphoproliferative syndrome (ALPS) is characterized by dysregulation of the immune system, due to an inability to regulate lymphocyte homeostasis through the process of lymphocyte apoptosis (a form of programmed cell death).",
"   </p>",
"   <p>",
"    This topic reviews management of ALPS. The epidemiology, genetics, pathogenesis, clinical manifestations, laboratory findings, diagnosis, and differential diagnosis of ALPS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567210\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ALPS focuses upon three aspects: treatment of disease manifestations,",
"    <span class=\"nowrap\">",
"     treatment/prevention",
"    </span>",
"    of disease and treatment complications, and curative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/1\">",
"     1",
"    </a>",
"    ]. Most experience is confined to patients with ALPS-FAS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567217\">",
"    <span class=\"h2\">",
"     Evaluation and monitoring following initial diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence and extent (disease manifestations and disease burden) of lymphoproliferation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autoimmunity should be determined before initiating therapy in an individual newly diagnosed with ALPS.",
"   </p>",
"   <p>",
"    This can be achieved with a combination of physical examination, imaging studies (eg, computed tomography [CT] scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positron emission tomography [PET] scans) of body areas thought to be involved (typically neck, chest, abdomen, and pelvis), and laboratory evaluation that includes measuring the size of the DNT cell compartment, the level of biomarkers (eg, vitamin B12, IL-10, FasL), blood counts, and the presence and nature of autoantibodies (eg, directed at blood cells). In patients deemed to need immunosuppressive therapy, one should also initiate a basic investigation of the integrity of immune system, particularly in young patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This evaluation should also include an assessment for lymphoma in patients with extensive lymphadenopathy, especially those with constitutional symptoms (eg fever, weight loss, night sweats). PET imaging may be helpful in this regard, since it is often difficult to distinguish between benign (ALPS-specific) lymphadenopathy and malignant lymphoma that are typically present concomitantly. PET scans can direct the surgeon to the node or nodes most likely to be of diagnostic value. Investigation for lymphoma is particularly important if immunosuppressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunomodulating agents are contemplated, since lymphoma development may be altered",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    masked by the use of these agents.",
"   </p>",
"   <p>",
"    There is some evidence to suggest that periodic surveillance using combined anatomical (ie, CT scan) and",
"    <span class=\"nowrap\">",
"     functional/metabolic",
"    </span>",
"    (ie, PET scan) imaging may be helpful, although more long-term data collection is needed to determine the cost to benefit ratio of expensive imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many laboratory findings, including the number of DNT cells and amounts of IL-10 and other biomarkers, not only serve a diagnostic purpose, but also can be used to monitor disease activity and response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567224\">",
"    <span class=\"h2\">",
"     Treatment of disease manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of disease manifestations is focused on the",
"    <span class=\"nowrap\">",
"     control/treatment",
"    </span>",
"    of lymphoproliferation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autoimmunity, and the treatment of lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. Treatment of lymphoproliferation and autoimmune disease in ALPS is based upon observational data and clinical experience, since there are no randomized trials. Therapy is individualized and the choice of agent depends upon many patient-specific factors and practitioner preference.",
"   </p>",
"   <p>",
"    Once initiated, immunosuppressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunomodulating therapy may be difficult to stop. The development of clinically relevant autoimmune cytopenias often indicates a new phase in the course of ALPS in a particular patient. Therapies that affect the immune system cannot be used for extended periods of time (years) without complications. For example, long-term use of glucocorticoids is associated with obesity, growth retardation, hypertension, cataracts,",
"    <span class=\"nowrap\">",
"     osteopenia/osteoporosis",
"    </span>",
"    leading to pathologic bone fractures, and diabetes, among others. Long-term use of antiproliferative T cell agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) may cause significant infections and renal function abnormalities. In addition, the immune system may not tolerate suppression for prolonged periods of time. Resolution of ALPS manifestations after years of therapy may be due to chronic immunosuppression rather than permanent remission of ALPS, and indicates the need for an assessment of overall immune competence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3894358\">",
"    <span class=\"h3\">",
"     Lymphoproliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of lymphoproliferation can be suppressed with the use of immunosuppressive agents, such as glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. The benefits of immunosuppression, however, are balanced by the side effects. In addition, lymphadenopathy, as well as splenomegaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatomegaly, return once immunosuppression is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, we suggest use of immunosuppressive therapy only for severe complications of lymphoproliferation (eg, airway obstruction)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in the presence of concomitant autoimmune manifestations.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil is typically well tolerated and requires little monitoring, making it our preferred agent with which to start therapy. It appears to induce modest improvement in lymphadenopathy and some improvement in splenomegaly (in some patients) and laboratory markers, such as lymphocyte counts and IL-10 and vitamin B12 levels. Dose and duration of therapy should be individualized to the patient. It is reasonable to determine a minimal dose that accomplishes the goals of therapy.",
"   </p>",
"   <p>",
"    Early experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    suggests that this agent may affect lymphoproliferation in a more sustained manner than other immunosuppressive agents, as demonstrated by more significant reduction in adenopathy, splenomegaly, and biomarkers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/10\">",
"     10",
"    </a>",
"    ]. This is balanced by the fact that sirolimus requires monitoring of levels, side effects, and complications, including infections. On the other hand, it is less mutagenic than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The author&rsquo;s approach is to determine if therapy is needed, based upon considerations discussed above. The author starts with the least immunosuppressive agent to accomplish treatment goals. In most patients, this can be achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , with or without a short course (approximately two to three weeks) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . The author use clinical response, physical examination (eg, degree of splenomegaly), and biomarkers to determine response and guide changes in drug dose (duration in therapy). In patients with insufficient response to mycophenolate, concomitant (or new) autoimmunity, or issues with mycophenolate, the author often initiates",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , starting with a dose to keep drug levels at the lower end of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567231\">",
"    <span class=\"h3\">",
"     Autoimmune manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune manifestations typically respond to short courses of immunosuppressive agents. Splenectomy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients with ALPS, due to the reported lack of sustained therapeutic benefit and increased incidence of postsplenectomy sepsis in both children and adults despite presplenectomy vaccinations and postsplenectomy antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      are effective in chronic recalcitrant autoimmune cytopenias and may spare glucocorticoid usage [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/8,10\">",
"       8,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      has been used successfully in the treatment of refractory cytopenias in ALPS, although it is not yet known how long affected individuals will remain in clinical remission [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/8,13\">",
"       8,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High-dose intravenous immune globulin (IVIG) is sufficient to control cytopenias in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe (recalcitrant) cytopenias or other potentially life-threatening autoimmune manifestations may require the use of plasmapheresis in combination with other modalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The author&rsquo;s approach is to use a combination of immunosuppressive and immunomodulating agents. Depending upon severity, this can be high-dose IVIG, a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and initiation of a T cell agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ) or switching to a more potent T cell agent (eg, from mycophenolate to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ). If high-dose IVIG does not",
"    <span class=\"nowrap\">",
"     achieve/maintain",
"    </span>",
"    remission (which is commonly the case in ALPS), the author uses",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as the immunomodulating agent, keeping in mind that the patient may require immune globulin replacement secondary to development of hypogammaglobulinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567238\">",
"    <span class=\"h3\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoma is treated according to conventional protocols (see specific treatment topics for each type of lymphoma). The presence of defective Fas-mediated apoptosis does not appear to hinder the response to chemotherapeutic agents or radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567245\">",
"    <span class=\"h2\">",
"     Prevention of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most complications are the results of immunosuppressive and immunomodulating agents and relate to the increased risk of infections. Intravenous or subcutaneous immune globulin therapy is warranted in some cases, as well as antimicrobials to prevent opportunistic, fungal, and viral infections. Infections caused by immunosuppressive and immunomodulating agents need to be thoroughly investigated and aggressively treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who have had a splenectomy, penicillin prophylaxis is strongly recommended and postsplenectomy boost vaccinations are suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567252\">",
"    <span class=\"h2\">",
"     Curative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is the only curative treatment for ALPS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Reduced-intensity preparative regimens offer lower morbidity and mortality than myeloablative preparative regimens and have been used successfully in primary immunodeficiencies. Our treatment protocol includes campath,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    as the reduced-intensity regimen. This conditioning regimen is well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/16\">",
"     16",
"    </a>",
"    ]. The status of ALPS disease activity needs to be carefully evaluated and the potential consequences of long-term treatments, including organ function, need to be compared with the risks of transplantation, before HCT is performed.",
"   </p>",
"   <p>",
"    Examples of transplant indications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphoma development, because of the potential for relapse after therapy",
"     </li>",
"     <li>",
"      Severe and recalcitrant autoimmune cytopenias, disease manifestations that can only be controlled by aggressive and sustained immunosuppression",
"     </li>",
"     <li>",
"      Patients with a severe disease phenotype at the time of diagnosis, including, but not limited, to patients with homozygous and compound heterozygous",
"      <em>",
"       FAS",
"      </em>",
"      defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567259\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling is recommended to provide patients and families with information on the nature of the disease, its inheritance, and implications for affected relatives and carriers. Patients with ALPS-sFAS did not inherit the genetic defect in",
"    <em>",
"     FAS",
"    </em>",
"    from either of the parents and do not appear to carry the mutation in their germline DNA. Consequently, their offspring will not inherit the somatic mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567266\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with ALPS have a favorable prognosis, with lymphadenopathy decreasing over time and autoimmune features remaining absent or manageable with limited need for immunosuppressive therapy. Some patients with particular mutations may have a better or poorer prognosis. However, it is difficult to determine which path each individual patient will follow, regardless of the genotype. Thus, long-term follow-up is indicated for the majority of patients to better predict and anticipate the natural history of each individual&rsquo;s disease. In addition, patients may need to be monitored for subsequent pathogenic events affecting Fas-mediated apoptosis, lymphocyte homeostasis in general, or other (still unknown) events [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/246/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mutations in",
"    <em>",
"     FAS",
"    </em>",
"    that affect the extracellular domains, particularly if these mutations cause defective apoptosis through haploinsufficiency (rather than dominant-negative interference), may have less severe disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    be less at-risk for lymphoma development.",
"   </p>",
"   <p>",
"    Patients with homozygous and compound heterozygous",
"    <em>",
"     FAS",
"    </em>",
"    mutations have a worse prognosis and typically require allogeneic bone marrow transplantation in order to survive.",
"   </p>",
"   <p>",
"    Longer-term follow-up of patients with ALPS-sFAS is needed to better assess the natural history of their clinical disease and their prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9567273\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder characterized by defective lymphocyte homeostasis, resulting from defective Fas-mediated apoptosis. (See",
"      <a class=\"local\" href=\"#H20229218\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=see_link\">",
"       \"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of ALPS focuses upon three aspects: treatment of disease manifestations, prevention and treatment of disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment complications, and curative therapy (hematopoietic cell transplantation). (See",
"      <a class=\"local\" href=\"#H9567210\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of immunosuppressive therapy only for severe complications of lymphoproliferation (eg, airway obstruction)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in the presence of concomitant autoimmune manifestations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Splenectomy is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for autoimmune manifestations in patients with ALPS, due to the reported lack of sustained therapeutic benefit and increased incidence of postsplenectomy sepsis. (See",
"      <a class=\"local\" href=\"#H9567224\">",
"       'Treatment of disease manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation is reserved for selected patients, such as those with lymphoma or severe, recalcitrant disease. (See",
"      <a class=\"local\" href=\"#H9567252\">",
"       'Curative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with ALPS have a favorable prognosis, with lymphadenopathy decreasing over time and autoimmune features remaining absent or manageable with limited need for immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H9567266\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/1\">",
"      Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood 2011; 118:5741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/2\">",
"      Rao VK, Carrasquillo JA, Dale JK, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol 2006; 81:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/3\">",
"      Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). Curr Pharm Des 2003; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/4\">",
"      Rieux-Laucat F, Blach&egrave;re S, Danielan S, et al. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood 1999; 94:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/5\">",
"      Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/6\">",
"      Van Der Werff Ten Bosch J, Otten J, Thielemans K. Autoimmune lymphoproliferative syndrome type III: an indefinite disorder. Leuk Lymphoma 2001; 41:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/7\">",
"      van der Werff Ten Bosch J, Schotte P, Ferster A, et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol 2002; 117:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/8\">",
"      Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/9\">",
"      Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol 2010; 148:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/10\">",
"      Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009; 145:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/11\">",
"      Oliveira VD, Zankl H, Rath T. Mutagenic and cytotoxic effects of immunosuppressive drugs on human lymphocyte cultures. Exp Clin Transplant 2004; 2:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/12\">",
"      Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011; 118:4798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/13\">",
"      Wei A, Cowie T. Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T&gt;C) affecting the Fas gene. Eur J Haematol 2007; 79:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/14\">",
"      Benkerrou M, Le Deist F, de Villartay JP, et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol 1997; 27:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/15\">",
"      Sleight BJ, Prasad VS, DeLaat C, et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant 1998; 22:375.",
"     </a>",
"    </li>",
"    <li>",
"     Bleesing J, unpublished observations.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/246/abstract/17\">",
"      Magerus-Chatinet A, Neven B, Stolzenberg MC, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest 2011; 121:106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16614 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_246=[""].join("\n");
var outline_f0_15_246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9567273\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20229218\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9567210\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9567217\">",
"      Evaluation and monitoring following initial diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9567224\">",
"      Treatment of disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3894358\">",
"      - Lymphoproliferation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9567231\">",
"      - Autoimmune manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9567238\">",
"      - Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9567245\">",
"      Prevention of complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9567252\">",
"      Curative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9567259\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9567266\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9567273\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_15_247="Superficial fibular nerve";
var content_f0_15_247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Normal and variant anatomy of the superficial fibular (peroneal) nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 673px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The superficial fibular (peroneal) nerve (in yellow) branches from the common fibular (peroneal) nerve at or below the proximal fibular head. The nerve descends in its 'normal' course (A) in the lateral compartment adjacent the intermuscular septum (in blue) of the anterior and lateral compartments. Between 27 and 43 percent of patients have the superficial fibular (peroneal) in either the anterior compartment (B) or both the anterior and the lateral compartments (C) of the leg. The superficial fibular (peroneal) nerve has also been found in close proximity to the septum that separates the anterior from the lateral compartment (D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn based on information from: Adkison DP, Bosse MJ, Gaccione DR, Gabriel KR. Anatomical variations in the course of the superficial peroneal nerve. J Bone Joint Surg Am 1991; 73:112.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_247=[""].join("\n");
var outline_f0_15_247=null;
var title_f0_15_248="Postpartum thyroiditis";
var content_f0_15_248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postpartum thyroiditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/248/contributors\">",
"     Kenneth D Burman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/248/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/248/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/15/248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum thyroiditis is a destructive thyroiditis induced by an autoimmune mechanism within one year after parturition. Postpartum thyroiditis can also occur after spontaneous or induced abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/1\">",
"     1",
"    </a>",
"    ]. It usually presents in one of three ways (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient hyperthyroidism alone",
"     </li>",
"     <li>",
"      Transient hypothyroidism alone",
"     </li>",
"     <li>",
"      Transient hyperthyroidism followed by hypothyroidism and then recovery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of postpartum thyroiditis are reviewed here. Other forms of thyroiditis and the diagnosis and management of thyroid dysfunction during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link\">",
"     \"Overview of thyroid disease in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of postpartum thyroiditis varies globally and ranges from 1 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In systematic reviews of prospective studies, the mean prevalence in the general population of women was approximately 7 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Higher rates, up to 25 percent, have been reported in women with type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], and the highest rates occur among women with a prior history of postpartum thyroiditis (pooled prevalence 42 percent) and in women with positive antithyroid peroxidase antibodies who had normal thyroid function during pregnancy (40 to 60 percent compared with 0 to 5 percent of women without antibodies) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/2\">",
"     2",
"    </a>",
"    ]. Postpartum thyroid dysfunction can occur in women already taking thyroid hormone replacement for hypothyroidism antedating pregnancy (eg, goitrous Hashimoto's thyroiditis), if they have some remaining thyroid tissue capable of producing thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most women recover and are euthyroid within one year postpartum. However, some women never recover from the initial hypothyroid phase and have permanent hypothyroidism or goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In addition, women with reversible hypothyroidism are at increased risk for developing permanent hypothyroidism in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]. In a study of 45 patients followed for eight years, 14 (31 percent) developed permanent hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/13\">",
"     13",
"    </a>",
"    ]. Progression to permanent hypothyroidism may be related to higher initial TSH concentrations and the antithyroid peroxidase antibody titer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/4,9,12,13\">",
"     4,9,12,13",
"    </a>",
"    ], maternal age, and female sex of the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum thyroiditis, like painless thyroiditis, is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis). The pathologic findings in the two disorders are similar (see",
"    <a class=\"local\" href=\"#H564660\">",
"     'Pathology'",
"    </a>",
"    below), and both are associated with particular HLA-B and HLA-D haplotypes, suggesting that inherited risk factors are important [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women destined to develop postpartum thyroiditis usually have high serum antithyroid peroxidase antibody concentrations early in pregnancy, which decline later (as immunologic tolerance increases during pregnancy) and then rise again after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, women destined to develop postpartum thyroiditis have subclinical thyroid autoimmune disease early in pregnancy and soon after it.",
"   </p>",
"   <p>",
"    Whatever factors initiate postpartum thyroiditis, the resulting thyroid inflammation damages thyroid follicles and activates proteolysis of the thyroglobulin stored within the follicles. The result is unregulated release of large amounts of thyroxine (T4) and triiodothyronine (T3) into the circulation, and subsequent hyperthyroidism. This state lasts only until the stores of thyroglobulin are exhausted, because new hormone synthesis ceases, not only because of damage to the thyroid follicular cells but also because of inhibition of thyrotropin (TSH) secretion by the increased serum T4 and T3 concentrations. As the inflammation subsides, the thyroid follicles regenerate and thyroid hormone synthesis and secretion resume (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ). There may be a transient period of hypothyroidism and increased TSH secretion before thyroid secretion becomes normal again.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17344418\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of postpartum thyroiditis can be identical to painless thyroiditis, but the course may be more variable. This apparent difference may reflect the greater ease of studying postpartum women prospectively than women in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 to 30 percent of women with postpartum thyroiditis have the characteristic sequence of hyperthyroidism, which usually begins one to four months after delivery and lasts two to eight weeks, followed by hypothyroidism, which lasts from about two weeks to six months, and then recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. However, 20 to 40 percent have only hyperthyroidism, and the remaining 40 to 50 percent have only hypothyroidism, which begins two to six months after delivery. Some women do not recover from the initial episode of hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms and signs of hyperthyroidism, when present, are typically mild and consist mainly of fatigue, weight loss, palpitations, heat intolerance, anxiety, irritability, tachycardia, and tremor. Similarly, hypothyroidism is also usually mild, leading to lack of energy, cold intolerance, constipation, sluggishness, and dry skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .) The symptoms that occur during the hyperthyroid phase are often only apparent retrospectively when the hypothyroid phase is diagnosed. Many of the symptoms of postpartum thyroiditis are inadvertently attributed to breastfeeding or the stresses of having a newborn child, as many otherwise normal postpartum women have fatigue, loss of energy, and anxiety, making the recognition of thyroid dysfunction difficult.",
"   </p>",
"   <p>",
"    While it has been suggested that hypothyroidism may be associated with or aggravate postpartum depression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], in subsequent prospective studies there was no association despite a high prevalence of postpartum thyroid dysfunction (11 to 12 percent) and postpartum depression (2 to 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most women with postpartum thyroiditis have a mildly enlarged, diffuse, nontender thyroid gland when their thyroid function is abnormal, which disappears with recovery. In some women, however, goiter is the presenting complaint.",
"   </p>",
"   <p>",
"    In addition to the usual clinical consequences of thyroid dysfunction, postpartum hypothyroidism may decrease milk volume [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical findings in patients with postpartum thyroiditis are similar to those of painless thyroiditis: high or high-normal serum free T4 and T3 concentrations and low serum TSH concentrations during the hyperthyroid phase, which may be overt or subclinical. During the hypothyroid phase, serum free T4 concentrations are low or low-normal, and serum TSH concentrations are high, consistent with either overt or subclinical hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .) In those women with hyperthyroidism followed by hypothyroidism, serum T4 concentrations may be low for several days to weeks before serum TSH concentrations rise above the normal range, because of TSH suppression during the hyperthyroid phase.",
"   </p>",
"   <p>",
"    Serum antithyroid peroxidase antibody concentrations are high in 60 to 85 percent of women with postpartum thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/10,16,22\">",
"     10,16,22",
"    </a>",
"    ], and are highest during the hypothyroid phase or soon thereafter. Routine laboratory studies are usually normal, but some women have a slightly increased erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C-reactive protein. No consistent abnormalities in numbers or types of peripheral blood (or intrathyroidal) T lymphocytes have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564660\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid biopsies in women with postpartum thyroiditis show lymphocytic infiltration, with occasional germinal centers, and disruption and collapse of thyroid follicles (lymphocytic thyroiditis) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. Fine needle aspiration biopsies reveal lymphocytes, thyroid follicular cells, and masses of colloid. During recovery, lymphocytic infiltration is still seen, and there may be some fibrosis, but the thyroid follicles are more normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8356863\">",
"    <span class=\"h2\">",
"     Radioiodine uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the hyperthyroid phase of postpartum thyroiditis, values for thyroid radioiodine uptake are low, usually less than 1 percent, compared with high values in Graves&rsquo; hyperthyroidism. However, breastfeeding is a strong relative contraindication to radioiodine (or technetium) administration, and must be suspended for at least several days until the breast milk is no longer radioactive. Because the hyperthyroid phase of postpartum thyroiditis is often only apparent retrospectively when the hypothyroid phase is diagnosed, radioiodine scanning is not usually necessary. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H994499#H994499\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17344246\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of postpartum thyroiditis is based upon clinical manifestations and thyroid function tests (TSH, free thyroxine). Clinicians caring for women after pregnancy should be alert to the possibility of postpartum thyroid dysfunction as a cause of many symptoms during this period. Routine measurement of thyroid function tests is not usually required, unless the woman has type 1 diabetes mellitus, had postpartum thyroiditis after a previous pregnancy, or was known to have high serum antithyroid peroxidase antibody concentrations prior to pregnancy. (See",
"    <a class=\"local\" href=\"#H522339\">",
"     'Screening'",
"    </a>",
"    below.) In addition, women with clinical manifestations of postpartum thyroiditis should have laboratory assessment of thyroid function. Because of the potential association between postpartum depression and postpartum hypothyroidism, and because hypothyroidism is a reversible cause of depression, women with postpartum depression should also be assessed for hypothyroidism.",
"   </p>",
"   <p>",
"    We typically measure TSH and free thyroxine (T4), rather than TSH alone, because thyroid function tests may fluctuate during the course of postpartum thyroiditis, and changes in TSH concentrations lag behind changes in serum free T4. If the TSH is low, T3 should also be measured.",
"   </p>",
"   <p>",
"    For women presenting with postpartum hypothyroidism, we do not routinely measure antithyroid peroxidase antibodies. If hypothyroidism resolves within several weeks without thyroid hormone replacement, the diagnosis of postpartum thyroiditis is confirmed.",
"   </p>",
"   <p>",
"    For women presenting with hyperthyroidism, radioiodine uptake (if not contraindicated, eg, active or recent breast feeding) or measurement of thyroid stimulating immunoglobulins (TSI) may help to differentiate postpartum thyroiditis from other causes of hyperthyroidism (ie, Graves&rsquo; disease). In addition, thyroid ultrasound may be useful to differentiate Graves&rsquo; disease from the hyperthyroid phase of postpartum thyroiditis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    below.) We obtain radioiodine uptake (if not contraindicated)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum TSI levels in women with clinical manifestations of Graves&rsquo; disease (ophthalmopathy), women with persistent hyperthyroidism (&gt;1 month), or severe hyperthyroidism (markedly elevated T3 &gt; T4). In women without these findings, we repeat thyroid function tests (TSH, free T4, T3) in three to four weeks. By that time, most women with postpartum thyroiditis will have improved, whereas those with Graves' hyperthyroidism will usually be unchanged or worse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2060224\">",
"    <span class=\"h2\">",
"     Hyperthyroid phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who present with clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory (high or high-normal serum free T4 and T3 and low serum TSH) manifestations of hyperthyroidism, it may be difficult to distinguish the hyperthyroid phase of postpartum thyroiditis from Graves' hyperthyroidism, which can also begin during the postpartum period, either as recurrent or new-onset hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary clinical differences between women with postpartum thyroiditis and those with Graves' hyperthyroidism are that hyperthyroidism in women with postpartum thyroiditis is usually mild (both clinically and biochemically), thyroid enlargement is minimal, and Graves' ophthalmopathy is absent. In contrast, women with Graves' hyperthyroidism are usually more symptomatic, have higher serum thyroid hormone concentrations, more thyroid enlargement, and may have ophthalmopathy or pretibial myxedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnosis of hyperthyroidism\", section on 'Determining the etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women without new-onset ophthalmopathy, the distinction may be difficult. In Graves&rsquo; disease, the serum T3 is typically elevated (in comparison with the upper limits of normal) to a greater degree than is the free T4, whereas the opposite is true in postpartum thyroiditis. Thus, a high T3 to T4 ratio (the value of which is assay and unit dependent) suggests Graves&rsquo; disease, while a ratio close to that of euthyroid patients suggests a destructive thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/24\">",
"     24",
"    </a>",
"    ]. The two disorders can often be distinguished by reevaluation in three to four weeks. By that time, most women with postpartum thyroiditis will have improved, whereas those with Graves' hyperthyroidism will be unchanged or worse.",
"   </p>",
"   <p>",
"    The two disorders can also be distinguished by measurements of serum thyroid stimulating immunoglobulins (TSI) or thyroid radioiodine uptake. Serum TSI levels are typically elevated in Graves&rsquo; hyperthyroidism but not in postpartum thyroiditis. Radioiodine uptake values are low in postpartum thyroiditis and high in Graves' hyperthyroidism. However, radioactive iodine testing should be avoided in women who are breast-feeding or have breast-fed recently. In addition, care must be taken to ensure topical iodine preparations were not used during delivery as the absorbed iodine may falsely lower the radioiodine uptake. When radioiodine uptake is contraindicated, thyroid ultrasound with Doppler flow may be helpful in differentiating these two conditions. Hypervascularity typically occurs with Graves' hyperthyroidism and there is decreased vascularity in hyperthyroidism associated with postpartum thyroiditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Autoimmune thyroid disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2060231\">",
"    <span class=\"h2\">",
"     Hypothyroid phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who present with clinical manifestations of hypothyroidism, the hypothyroid phase of postpartum thyroiditis (low or low-normal serum free T4 and high TSH) must be differentiated from lymphocytic hypophysitis, which also may occur during late pregnancy or the postpartum period. Lymphocytic hypophysitis may cause deficiency of TSH as well as one or more additional pituitary hormones including ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Spontaneous recovery of pituitary gland function or, alternatively, persistent and chronic hypopituitarism may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/27\">",
"     27",
"    </a>",
"    ]. In lymphocytic hypophysitis, the serum TSH is expected to be normal or low in the context of a low free T4, whereas in hypothyroidism with postpartum thyroiditis, the TSH should be elevated in conjunction with a decreased FT4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H9#H9\">",
"     \"Causes of hypopituitarism\", section on 'Hypophysitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postpartum thyroiditis is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.) It is not necessary to measure antithyroid peroxidase antibodies in women with postpartum hypothyroidism. Women who do not recover from the initial hypothyroid phase within one year postpartum likely have chronic autoimmune thyroiditis and permanent hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522339\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of postpartum thyroiditis raises the question of whether screening is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/28\">",
"     28",
"    </a>",
"    ]. This could be done by periodic clinical evaluation or serum TSH assay after delivery. Alternatively, serum antithyroid peroxidase antibodies could be measured, either early in pregnancy or soon after delivery. High antibody concentrations at these times predict (but not with certainty) the later development of postpartum thyroiditis, and low concentrations make it very unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/11,15,16,29\">",
"     11,15,16,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the Endocrine Society clinical guidelines that there is insufficient evidence to support a recommendation for screening all pregnant women for postpartum thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/3\">",
"     3",
"    </a>",
"    ]. However, women at highest risk for developing postpartum thyroiditis (eg, antithyroid peroxidase antibody positive, type 1 diabetes, previous episode of postpartum thyroiditis) should have a serum TSH measurement at three and six months postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/3\">",
"     3",
"    </a>",
"    ]. If the TSH level is abnormal, it should be repeated along with a free thyroxine level and T3 (if TSH is low), within one to two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established therapies to prevent the occurrence of postpartum thyroiditis in patients with antithyroid peroxidase antibodies. Administration of T4 or iodine to pregnant women with high serum antithyroid antibody concentrations did not prevent postpartum thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    supplementation may decrease inflammatory activity in pregnant women with autoimmune hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/32\">",
"     32",
"    </a>",
"    ], and may reduce the risk of postpartum thyroiditis in women who are positive for thyroid peroxidase (TPO) antibodies. This was illustrated in a trial of 151 TPO-positive women randomly assigned to receive selenium (200 mcg daily) or placebo (beginning at about the 12",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation). The prevalence of postpartum thyroiditis was significantly lower in the selenium group (22 of 77 women [29 percent] versus 36 of 74 [49 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/33\">",
"     33",
"    </a>",
"    ]. The routine clinical application of this supplementation requires further study, especially since selenium deficiency may have existed in this cohort from Italy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of randomized trials comparing different treatment strategies, treatment recommendations are based upon observational studies and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/3,7-9,13\">",
"     3,7-9,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach, which is similar to that of the Endocrine Society [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/3\">",
"     3",
"    </a>",
"    ] and the American Thyroid Association [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/5\">",
"     5",
"    </a>",
"    ], is outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of women with postpartum thyroiditis need no treatment during either the hyperthyroid or the hypothyroid phases of their illness. However, thyroid function tests (TSH, free T4, and if hyperthyroid, T3) should be monitored every four to eight weeks to confirm resolution of biochemical abnormalities or to detect the development of more severe hypothyroidism, indicating possible permanent hypothyroidism.",
"     </li>",
"     <li>",
"      Women who have bothersome symptoms of hyperthyroidism can be treated with 40 to 120 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      or 25 to 50 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      daily until their serum T3 and serum free T4 concentrations are normal. For women who are breastfeeding, propranolol is preferred because, due to high plasma protein binding, it is not concentrated in breast milk as much as other beta blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/34\">",
"       34",
"      </a>",
"      ]. In the hyperthyroid phase, radioiodine treatment and antithyroid drugs (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      ) are of no value because the synthesis of T4 and T3 is decreased, not increased as in most other disorders causing hyperthyroidism.",
"     </li>",
"     <li>",
"      Women with symptomatic hypothyroidism should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      (T4) (typically about 50 to 100",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      although requirements may vary), irrespective of the degree of TSH elevation. In asymptomatic women, we prefer to treat when the TSH exceeds 10",
"      <span class=\"nowrap\">",
"       mU/L.",
"      </span>",
"      Asymptomatic women who have a mildly elevated serum TSH (between the upper limit of the normal range and 10",
"      <span class=\"nowrap\">",
"       mU/L),",
"      </span>",
"      and who are not planning another pregnancy, do not necessarily require intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of thyroid hormone therapy once initiated is uncertain. Since postpartum thyroid dysfunction is often transient, many experts favor weaning T4 after 6 to 12 months, unless the woman is pregnant, attempting pregnancy, or breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/4\">",
"     4",
"    </a>",
"    ]. The dose can be halved and thyroid tests (TSH, free T4) reevaluated in six to eight weeks. Up to 30 percent of women never recover from the initial hypothyroid phase, and a rising TSH level is indicative of persistent hypothyroidism, requiring long-term T4. In some reports, high titers of antithyroid peroxidase antibodies and the severity of the initial hypothyroid phase predicted the development of permanent hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/7,12,13,35\">",
"     7,12,13,35",
"    </a>",
"    ]. Thus, in women with very elevated initial TSH values (&gt;50 or 100",
"    <span class=\"nowrap\">",
"     mU/L),",
"    </span>",
"    an alternative approach is to continue thyroid hormone indefinitely.",
"   </p>",
"   <p>",
"    Because there are no prospective, controlled data confirming the best approach, the decision to withdraw thyroid hormone therapy should be based upon individual patient characteristics and preferences. We favor withdrawing thyroid hormone therapy in most women after 12 months of therapy. Monitoring for persistent hypothyroidism is required after thyroid hormone withdrawal, initially after six to eight weeks, three months, six months, and then annually if thyroid tests remain normal.",
"   </p>",
"   <p>",
"    Any woman who has had postpartum thyroiditis should be told that recurrence is likely after future pregnancies and that she is at substantial risk for the later development of hypothyroidism or goiter, and she should be educated regarding the possible development of symptoms. For women who have fully recovered from postpartum thyroiditis, we measure serum TSH levels annually, particularly within 5 to 10 years after the initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/248/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=see_link\">",
"       \"Patient information: Thyroiditis after pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521341\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postpartum thyroiditis is a destructive thyroiditis induced by an autoimmune mechanism within one year after parturition. It occurs more often in women with a previous history of postpartum thyroiditis, positive antithyroid peroxidase antibody titers, and type 1 diabetes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 20 to 30 percent of women with postpartum thyroiditis have the characteristic sequence of hyperthyroidism, which usually begins one to four months after delivery and lasts two to eight weeks, followed by hypothyroidism, which also lasts from about two weeks to six months, and then recovery (",
"      <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"       figure 1",
"      </a>",
"      ). However, other women have only hyperthyroidism or only hypothyroidism. The symptoms and signs of hyperthyroidism, when present, are typically mild and consist mainly of fatigue, weight loss, palpitations, heat intolerance, anxiety, irritability, tachycardia, and tremor. Similarly, hypothyroidism is also usually mild, leading to lack of energy, cold intolerance, constipation, sluggishness, and dry skin. The biochemical findings depend upon the phase of postpartum thyroiditis: high or high-normal serum free T4 and T3 and low serum TSH during the hyperthyroid phase, and low or low-normal serum free T4 concentrations and high serum TSH during the hypothyroid phase. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of postpartum thyroiditis is based upon clinical manifestations and thyroid function tests. In women with symptoms or signs of hyperthyroidism or hypothyroidism in the postpartum period, we measure TSH and free thyroxine, rather than TSH alone. Thyroid function tests may fluctuate during the course of postpartum thyroiditis, and changes in TSH concentrations lag behind changes in serum free T4. If the TSH is low, T3 should also be measured. (See",
"      <a class=\"local\" href=\"#H17344246\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women presenting with postpartum hypothyroidism, we do not routinely measure antithyroid peroxidase antibodies. If hypothyroidism resolves within several weeks without thyroid hormone replacement, the diagnosis of postpartum thyroiditis is confirmed. For women presenting with postpartum hyperthyroidism, we obtain radioiodine uptake (if not contraindicated) or serum TSI levels in women with clinical manifestations of Graves&rsquo; disease (ophthalmopathy), women with persistent hyperthyroidism (&gt;1 month), or severe hyperthyroidism (markedly elevated T3 &gt; T4). In women without these findings, we repeat thyroid function tests (TSH, free T4, T3) in three to four weeks. By that time, most women with postpartum thyroiditis will have improved, whereas those with Graves' hyperthyroidism will be unchanged or worse. (See",
"      <a class=\"local\" href=\"#H17344246\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women at high risk for developing postpartum thyroiditis (eg, previously known to be thyroid peroxidase antibody positive, type 1 diabetes, prior history of postpartum thyroiditis), we suggest routine screening for postpartum thyroiditis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically measure a TSH level three and six months postpartum. If the TSH level is abnormal, it should be repeated along with a free thyroxine level and T3 (if TSH is low), within one to two weeks. (See",
"      <a class=\"local\" href=\"#H522339\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most women with postpartum thyroiditis have only mild symptoms during the hyperthyroid phase and do not require any treatment. Such women should have repeat thyroid tests in four to eight weeks to confirm resolution of hyperthyroidism. Beta blockers may be useful to relieve bothersome palpitations or tremulousness in symptomatic women. In breastfeeding women, we prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      because it has the lowest transfer into milk. There is no role for antithyroid drugs (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      ) or radioiodine in the treatment of the hyperthyroid phase of postpartum thyroiditis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link&amp;anchor=H4#H4\">",
"       \"Hyperthyroidism during pregnancy: Treatment\", section on 'Beta blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      During the hypothyroid phase of postpartum thyroiditis, symptomatic women require treatment with thyroxine (T4). For asymptomatic women with a TSH level &ge;10",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      we also suggest T4 replacement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We do not routinely treat asymptomatic women with TSH levels below 10",
"      <span class=\"nowrap\">",
"       mU/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most women recover and are euthyroid within one year postpartum. Thus, we typically continue thyroid hormone for one year before attempting withdrawal. However, up to 30 percent of women never recover from the initial hypothyroid phase and have permanent hypothyroidism. Women with reversible hypothyroidism are also at increased risk for developing permanent hypothyroidism in the future and, therefore, require yearly monitoring of TSH. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/1\">",
"      Marqusee E, Hill JA, Mandel SJ. Thyroiditis after pregnancy loss. J Clin Endocrinol Metab 1997; 82:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/2\">",
"      Nicholson WK, Robinson KA, Smallridge RC, et al. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid 2006; 16:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/3\">",
"      De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/4\">",
"      Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab 2012; 97:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/5\">",
"      Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/6\">",
"      Caix&agrave;s A, Albareda M, Garc&iacute;a-Patterson A, et al. Postpartum thyroiditis in women with hypothyroidism antedating pregnancy? J Clin Endocrinol Metab 1999; 84:4000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/7\">",
"      Azizi F. The occurrence of permanent thyroid failure in patients with subclinical postpartum thyroiditis. Eur J Endocrinol 2005; 153:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/8\">",
"      Tachi J, Amino N, Tamaki H, et al. Long term follow-up and HLA association in patients with postpartum hypothyroidism. J Clin Endocrinol Metab 1988; 66:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/9\">",
"      Othman S, Phillips DI, Parkes AB, et al. A long-term follow-up of postpartum thyroiditis. Clin Endocrinol (Oxf) 1990; 32:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/10\">",
"      Nikolai TF, Turney SL, Roberts RC. Postpartum lymphocytic thyroiditis. Prevalence, clinical course, and long-term follow-up. Arch Intern Med 1987; 147:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/11\">",
"      Lazarus JH, Ammari F, Oretti R, et al. Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract 1997; 47:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/12\">",
"      Stuckey BG, Kent GN, Ward LC, et al. Postpartum thyroid dysfunction and the long-term risk of hypothyroidism: results from a 12-year follow-up study of women with and without postpartum thyroid dysfunction. Clin Endocrinol (Oxf) 2010; 73:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/13\">",
"      Lucas A, Pizarro E, Granada ML, et al. Postpartum thyroiditis: long-term follow-up. Thyroid 2005; 15:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/14\">",
"      Kologlu M, Fung H, Darke C, et al. Postpartum thyroid dysfunction and HLA status. Eur J Clin Invest 1990; 20:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/15\">",
"      Stagnaro-Green A, Roman SH, Cobin RH, et al. A prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction. J Clin Endocrinol Metab 1992; 74:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/16\">",
"      Lazarus JH, Hall R, Othman S, et al. The clinical spectrum of postpartum thyroid disease. QJM 1996; 89:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/17\">",
"      Harris B, Othman S, Davies JA, et al. Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ 1992; 305:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/18\">",
"      Lazarus JH, Othman S. Thyroid disease in relation to pregnancy. Clin Endocrinol (Oxf) 1991; 34:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/19\">",
"      Kent GN, Stuckey BG, Allen JR, et al. Postpartum thyroid dysfunction: clinical assessment and relationship to psychiatric affective morbidity. Clin Endocrinol (Oxf) 1999; 51:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/20\">",
"      Lucas A, Pizarro E, Granada ML, et al. Postpartum thyroid dysfunction and postpartum depression: are they two linked disorders? Clin Endocrinol (Oxf) 2001; 55:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/21\">",
"      Miyake A, Tahara M, Koike K, Tanizawa O. Decrease in neonatal suckled milk volume in diabetic women. Eur J Obstet Gynecol Reprod Biol 1989; 33:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/22\">",
"      Gerstein HC. How common is postpartum thyroiditis? A methodologic overview of the literature. Arch Intern Med 1990; 150:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/23\">",
"      Mizukami Y, Michigishi T, Nonomura A, et al. Postpartum thyroiditis. A clinical, histologic, and immunopathologic study of 15 cases. Am J Clin Pathol 1993; 100:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/24\">",
"      Izumi Y, Hidaka Y, Tada H, et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 2002; 57:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/25\">",
"      Patel MC, Guneratne N, Haq N, et al. Peripartum hypopituitarism and lymphocytic hypophysitis. QJM 1995; 88:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/26\">",
"      Landek-Salgado MA, Gutenberg A, Lupi I, et al. Pregnancy, postpartum autoimmune thyroiditis, and autoimmune hypophysitis: intimate relationships. Autoimmun Rev 2010; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/27\">",
"      Unl&uuml;hizarci K, Bayram F, Colak R, et al. Distinct radiological and clinical appearance of lymphocytic hypophysitis. J Clin Endocrinol Metab 2001; 86:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/28\">",
"      Amino N, Tada H, Hidaka Y, et al. Therapeutic controversy: Screening for postpartum thyroiditis. J Clin Endocrinol Metab 1999; 84:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/29\">",
"      Premawardhana LD, Parkes AB, John R, et al. Thyroid peroxidase antibodies in early pregnancy: utility for prediction of postpartum thyroid dysfunction and implications for screening. Thyroid 2004; 14:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/30\">",
"      K&auml;mpe O, Jansson R, Karlsson FA. Effects of L-thyroxine and iodide on the development of autoimmune postpartum thyroiditis. J Clin Endocrinol Metab 1990; 70:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/31\">",
"      N&oslash;hr SB, J&oslash;rgensen A, Pedersen KM, Laurberg P. Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: is iodine supplementation safe? J Clin Endocrinol Metab 2000; 85:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/32\">",
"      Mazokopakis EE, Papadakis JA, Papadomanolaki MG, et al. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid 2007; 17:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/33\">",
"      Negro R, Greco G, Mangieri T, et al. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab 2007; 92:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/34\">",
"      Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 2002; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/248/abstract/35\">",
"      Premawardhana LD, Parkes AB, Ammari F, et al. Postpartum thyroiditis and long-term thyroid status: prognostic influence of thyroid peroxidase antibodies and ultrasound echogenicity. J Clin Endocrinol Metab 2000; 85:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7831 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_248=[""].join("\n");
var outline_f0_15_248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H521341\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17344418\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564660\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8356863\">",
"      Radioiodine uptake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17344246\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2060224\">",
"      Hyperthyroid phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2060231\">",
"      Hypothyroid phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522339\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H521341\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7831|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/16/28942\" title=\"figure 1\">",
"      Course of thyroiditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=related_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=related_link\">",
"      Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=related_link\">",
"      Patient information: Thyroiditis after pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_15_249="Pathophysiology of ischemic stroke";
var content_f0_15_249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of ischemic stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/249/contributors\">",
"     Arshad Majid, MB, ChB, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/249/contributors\">",
"     Daniel B Zemke, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/249/contributors\">",
"     Mounzer Kassab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/249/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/249/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/15/249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21816440\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term ischemic stroke is used to describe a variety of conditions in which blood flow to part or all of the brain is reduced, resulting in tissue damage. Although in some cases this may be a chronic condition, most strokes occur acutely. Research over the last four decades has resulted in a significant expansion of our knowledge and understanding of the molecular and cellular processes that underlie ischemia-induced cellular injury.",
"   </p>",
"   <p>",
"    The goal of this review is to provide an overview of the underlying factors, such as the hemodynamic changes and molecular and cellular pathways, which are involved in stroke-related brain injury. A better understanding of these processes may help in the development of new therapies that are needed to treat this devastating disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21816470\">",
"    <span class=\"h1\">",
"     STROKE SUBTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and clinical classification of ischemic stroke subtypes is reviewed here briefly and discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology and classification of stroke\", section on 'Brain ischemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute ischemic stroke subtypes are often classified in clinical studies using a system developed by investigators of the TOAST trial, based upon the underlying cause (",
"    <a class=\"graphic graphic_table graphicRef62571 \" href=\"UTD.htm?3/28/3531\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/1\">",
"     1",
"    </a>",
"    ]. Under this system, strokes are classified into the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large artery atherosclerosis",
"     </li>",
"     <li>",
"      Cardioembolism",
"     </li>",
"     <li>",
"      Small vessel occlusion",
"     </li>",
"     <li>",
"      Stroke of other, unusual, determined etiology",
"     </li>",
"     <li>",
"      Stroke of undetermined etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ischemic strokes are due to a reduction or complete blockage of blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2\">",
"     2",
"    </a>",
"    ]. This reduction can be due to decreased systemic perfusion, severe stenosis or occlusion of a blood vessel. Decreased systemic perfusion can be the result of low blood pressure, heart failure, or loss of blood. Determination of the type of stroke can influence treatment to be used. The main causes of ischemia are thrombosis, embolization, and lacunar infarction from small vessel disease. Ischemic strokes represent about 80 percent of all strokes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical diagnosis of stroke subtypes\", section on 'Incidence and prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombosis refers to obstruction of a blood vessel due to a localized occlusive process within a blood vessel [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2\">",
"       2",
"      </a>",
"      ]. The obstruction may occur acutely or gradually. In many cases, underlying pathology such as atherosclerosis may cause narrowing of the diseased vessel. This may lead to restriction of blood flow gradually, or in some cases, platelets may adhere to the atherosclerotic plaque forming a clot leading to acute occlusion of the vessel. Atherosclerosis usually affects larger extracranial and intracranial vessels. In some cases, acute occlusion of a vessel unaffected by atherosclerosis may occur because of a hypercoagulable state. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link&amp;anchor=H4#H4\">",
"       \"Etiology and classification of stroke\", section on 'Thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Embolism refers to clot or other material formed elsewhere within the vascular system that travels from the site of formation and lodges in distal vessels causing blockage of those vessel and ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2\">",
"       2",
"      </a>",
"      ]. The heart is a common source of this material, although other arteries may also be sources of this embolic material (artery to artery embolism). In the heart, clots may form on valves or chambers. Tumors, venous clots, septic emboli, air and fat can also embolize and cause stroke. Embolic strokes tend to be cortical and are more likely to undergo hemorrhagic transformation, probably due to vessel damage caused by the embolus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link&amp;anchor=H7#H7\">",
"       \"Etiology and classification of stroke\", section on 'Embolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lacunar infarction occurs as a result of small vessel disease. Smaller penetrating vessels are more commonly affected by chronic hypertension leading to hyperplasia of the tunica media of these vessels and deposition of fibrinoid material leading to lumen narrowing and occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2\">",
"       2",
"      </a>",
"      ]. Lacunar strokes can occur anywhere in the brain but are typically seen in sub-cortical areas. Atheroma can also encroach on the orifices of smaller vessels leading to occlusion and stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"       \"Lacunar infarcts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonatherosclerotic abnormalities of the cerebral vasculature, whether inherited or acquired, predispose to ischemic stroke at all ages, but particularly in younger adults and children. These can be divided into noninflammatory and inflammatory etiologies. The following list, though not exhaustive, highlights the major nonatherosclerotic vasculopathies associated with ischemic stroke:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arterial dissection (",
"      <a class=\"graphic graphic_figure graphicRef57866 \" href=\"UTD.htm?17/18/17698\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromuscular dysplasia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vasculitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"       \"Classification of and approach to the vasculitides in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=see_link\">",
"       \"Classification and incidence of childhood vasculitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Moyamoya disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link\">",
"       \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sickle cell disease arteriopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Focal cerebral arteriopathy of childhood (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H9#H9\">",
"       \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'Focal cerebral arteriopathy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased systemic perfusion due to systemic hypotension may produce generalized ischemia to the brain [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2\">",
"       2",
"      </a>",
"      ]. This is most critical in the borderzone (or watershed) areas, which are territories that occupy the boundary region of two adjacent arterial supply zones. The ischemia caused by hypotension may be asymmetric due to preexisting vascular lesions. Areas of the brain commonly affected include the hippocampal pyramidal cells, cerebellar Purkinje cells, and cortical laminar cells discussed below. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link&amp;anchor=H11#H11\">",
"       \"Etiology and classification of stroke\", section on 'Systemic hypoperfusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1222833\">",
"    <span class=\"h1\">",
"     CEREBRAL AUTOREGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal conditions, the rate of cerebral blood flow is primarily determined by the amount of resistance within cerebral blood vessels, which is directly related to their diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/3\">",
"     3",
"    </a>",
"    ]. Dilation of vessels leads to an increased volume of blood in the brain and increased cerebral blood flow, whereas constriction of vessels has the opposite effect. Cerebral blood flow is also determined by variation in the cerebral perfusion pressure.",
"   </p>",
"   <p>",
"    Cerebral autoregulation is the phenomenon by which cerebral blood flow is maintained at a relatively constant level despite moderate variations in perfusion pressure. The mechanism by which autoregulation occurs is not well understood, and may involve multiple pathways. Evidence suggests that the smooth muscle in cerebral vessels can respond directly to changes in perfusion pressure, contracting when pressure increases and relaxing when pressure drops. Reductions in cerebral blood flow may also lead to dilation of blood vessels through the release of vasoactive substances, although the molecules responsible for this have not been identified. The endothelial release of nitric oxide also appears to play a role in autoregulation.",
"   </p>",
"   <p>",
"    Maintenance of cerebral blood flow by autoregulation typically occurs within a mean arterial pressure range of 60 to 150 mmHg. The upper and lower limits vary between individuals, however. Outside of this range, the brain is unable to compensate for changes in perfusion pressure, and the cerebral blood flow increases or decreases passively with corresponding changes in pressure, resulting in the risk of ischemia at low pressures and edema at high pressures (",
"    <a class=\"graphic graphic_figure graphicRef66923 \" href=\"UTD.htm?23/22/23918\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1222840\">",
"    <span class=\"h2\">",
"     Cerebral autoregulation during stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral autoregulation is impaired during some disease conditions, including ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. As cerebral perfusion pressure falls, cerebral blood vessels dilate to increase cerebral blood flow. A decrease in perfusion pressure beyond the ability of the brain to compensate results in a reduction in cerebral blood flow. Initially, the oxygen extraction fraction is increased in order to maintain levels of oxygen delivery to the brain. As the cerebral blood flow continues to fall, other mechanisms come into play (",
"    <a class=\"graphic graphic_figure graphicRef77705 \" href=\"UTD.htm?10/46/10990\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Inhibition of protein synthesis occurs at flow rates below 50",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per minute. At 35",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per minute, protein synthesis ceases completely and glucose utilization is transiently increased. At 25",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per minute, glucose utilization drops dramatically with the onset of anaerobic glycolysis, resulting in tissue acidosis from the accumulation of lactic acid. Neuronal electrical failure occurs at 16 to 18",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per minute, and failure of membrane ion homeostasis occurs at 10 to 12",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per minute. This level typically marks the threshold for the development of infarct (",
"    <a class=\"graphic graphic_figure graphicRef77705 \" href=\"UTD.htm?10/46/10990\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In hypertensive individuals, autoregulation has adapted to occur at higher arterial pressures. Reduction of blood pressure to normal levels could actually exacerbate the derangement to autoregulation that occurs during stroke and lead to a further decrease in cerebral blood flow (",
"    <a class=\"graphic graphic_figure graphicRef66923 \" href=\"UTD.htm?23/22/23918\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21816535\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF REDUCTION IN BLOOD FLOW DURING STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human brain is exquisitely sensitive and susceptible to even short durations of ischemia. The brain is responsible for a large part of the body's metabolism and receives about 20 percent of the cardiac output although it is only 2 percent of total body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/3\">",
"     3",
"    </a>",
"    ]. The brain contains little or no energy stores of its own, and therefore relies on the blood for their delivery. Even brief deprivation can lead to death of the affected brain tissue. During stroke, reduction of blood flow to a portion or all of the brain results in a deprivation of glucose and oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most strokes are caused by focal ischemia, affecting only a portion of the brain, typically involving a single blood vessel and its downstream branches. The region directly surrounding the vessel is the most affected. Within this region, cells in a central core of tissue will be irreversibly damaged and die by necrosis if the duration of ischemia is long enough. At distances farther from the affected vessel, some cells may receive a small amount of oxygen and glucose by diffusion from collateral vessels. These cells do not die immediately, and can recover if blood flow is restored in a timely manner. The central core of tissue destined to die, or containing tissue that is already dead, is called the infarct. The region of potentially salvageable tissue is known as the penumbra.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21816542\">",
"    <span class=\"h2\">",
"     Mechanisms of ischemic cell injury and death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain ischemia initiates a cascade of events that eventually lead to cell death, including depletion of ATP, changes in ionic concentrations of sodium, potassium, and calcium, increased lactate, acidosis, accumulation of oxygen free radicals, intracellular accumulation of water, and activation of proteolytic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a consequence of the electrical failure that occurs during ischemia, the release of the excitatory amino acid glutamate at neuronal synapses is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2\">",
"     2",
"    </a>",
"    ]. This leads to the activation of glutamate receptors and the opening of ion channels that allow potassium ions to exit the cell and sodium and calcium ions to enter, which has a number of physiologic effects. The primary glutamate receptor subtype involved in ischemic damage is the N-methyl-D-aspartate (NMDA) receptor. In addition, the alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and metabotropic glutamate receptors are thought to play a role. Activation of these receptors leads to membrane depolarization and increased calcium influx.",
"   </p>",
"   <p>",
"    Numerous cellular signaling pathways respond to calcium levels, and the influx of calcium resulting from glutamate receptor stimulation leads to their activation. These pathways have both beneficial and detrimental effects. The influx of sodium ions is balanced by the influx of water into the cell, leading to edema. Sodium influx also causes reversal of the normal process of glutamate uptake by astrocyte glutamate transporters, resulting in increased glutamate release [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. As a result of its increased release and decreased uptake, glutamate accumulates to excessive levels and leads to continuous stimulation. This condition is often referred to as excitotoxicity.",
"   </p>",
"   <p>",
"    Another effect of NMDA receptor activation is the production of nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/12\">",
"     12",
"    </a>",
"    ]. The activity of nitric oxide synthase (NOS) and the total amount of nitric oxide present in the brain are increased following exposure to hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitric oxide is an important signaling molecule within the body and can be beneficial at normal physiologic levels. As an example, endothelial nitric oxide synthase (eNOS) leads to the production of low levels of nitric oxide that cause vasodilation and increase blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/14\">",
"     14",
"    </a>",
"    ]. However, neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS) result in larger amounts of nitric oxide that may lead to brain injury. Nitric oxide is a free radical and reacts directly with cellular components to damage them. Nitric oxide can also react with another free radical, superoxide, to produce the highly reactive peroxynitrite. Peroxynitrite causes single strand breaks in DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/15\">",
"     15",
"    </a>",
"    ]. This results in the activation of DNA repair enzymes, which consume vital energy needed for other processes. DNA damage also may activate the process of apoptosis, leading to cell death.",
"   </p>",
"   <p>",
"    The production of reactive oxygen species, a normal byproduct of oxidative metabolism, is also increased during ischemia. Like nitric oxide, they can react with and damage cellular components. Injury to the plasma membrane of a cell can lead to the inability to control ion flux, resulting in mitochondrial failure. Reactive oxygen species, as well as calcium influx and other factors, can also permeabilize the mitochondrial membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/16\">",
"     16",
"    </a>",
"    ]. This leads to metabolic failure as well as the release of initiators of apoptosis and DNA damage. Metabolic failure results in the depletion of cellular ATP levels. ATP is required for nuclear condensation and DNA degradation in the final stages of apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/17\">",
"     17",
"    </a>",
"    ]. In the absence of ATP, cell death occurs by necrosis rather than apoptosis (see below).",
"   </p>",
"   <p>",
"    The release of byproducts from cellular damage and death by necrosis activates components of the inflammatory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/18\">",
"     18",
"    </a>",
"    ]. The role that inflammation plays during ischemia is mixed, having both positive and negative effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/19\">",
"     19",
"    </a>",
"    ]. On the one hand, inflammation results in an increase in blood flow to the ischemic region, which may deliver vital glucose and oxygen to cells. On the other hand, increased blood flow may also deliver more calcium to the area, resulting in increased tissue damage.",
"   </p>",
"   <p>",
"    Inflammation also results in the migration of activated leukocytes to damaged tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/20\">",
"     20",
"    </a>",
"    ]. Although these leukocytes may remove damaged and necrotic tissue, they also release cytokines to attract additional inflammatory cells. Under severe inflammatory conditions, these cytokines can accumulate to toxic levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21816549\">",
"    <span class=\"h3\">",
"     Necrosis and apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell death following cerebral ischemia or stroke can occur by either necrosis or by apoptosis. The process of necrosis is not well understood. In early stages, cellular chromatin becomes uniformly compacted, the endoplasmic reticulum is dilated, and ribosomes are dispersed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/21\">",
"     21",
"    </a>",
"    ]. In later stages, swelling of the cell and mitochondria is followed by rupture of the nuclear, organelle, and plasma membranes, leading to the release of cellular material into the surrounding environment. This release of material results in the stimulation of inflammatory processes within the brain.",
"   </p>",
"   <p>",
"    Apoptosis is highly regulated and has been studied in more detail than necrosis. As in necrosis, the chromatin begins to condense during early stages of apoptosis. Instead of cellular swelling, however, the contents of the cytoplasm also condense, and the mitochondria and other organelles remain intact. In later stages, the nucleus is broken into discrete fragments and the entire contents of the cell are divided into membrane bound bodies that are subsequently phagocytosed by macrophages.",
"   </p>",
"   <p>",
"    There are three known pathways by which apoptosis can be initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mitochondrial permeabilization",
"     </li>",
"     <li>",
"      Death receptor (Fas) pathway",
"     </li>",
"     <li>",
"      Endoplasmic reticulum stress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most well-known pathway involves permeabilization of the mitochondria and release of cytochrome c into the cytoplasm. Activation of membrane-bound Fas, the so called \"death receptor,\" and the accumulation of misfolded proteins at the endoplasmic reticulum during stress, can also lead to apoptosis. These initiators all lead to the activation of caspases that cleave cellular proteins and eventually cause cell death. Caspase-independent mechanisms of apoptosis have also been proposed.",
"   </p>",
"   <p>",
"    The pattern of cell death after cerebral ischemia, as seen in animal models, depends on the nature of the insult to cerebral tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/23\">",
"     23",
"    </a>",
"    ]. In global cerebral ischemia, such as occurs after cardiac arrest and resuscitation or transient severe systemic hypotension, the entire brain is exposed to ischemia. Formation of infarct is not immediate, but rather occurs after a delay of 12 hours to several days. Cell death is limited to those regions of the brain that are particularly susceptible to ischemic damage, such as the CA1 and CA4 regions of the hippocampus, the striatum, and cortical layers two and five. Cell death in these regions occurs primarily by apoptosis.",
"   </p>",
"   <p>",
"    Focal cerebral ischemia is a more common pattern than global ischemia in human stroke. In animal models of focal ischemia, changes in cell morphology are visible microscopically as early as two to three hours after the insult, and the infarct develops rapidly over a period of 6 to 24 hours. Cell death occurs by necrosis in the core, with apoptotic cells located on the periphery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition to the type of insult, the duration of ischemia also affects the pattern by which cell death occurs. Longer ischemic insults produce greater damage to cerebral tissue, resulting in an increased proportion of necrosis and decreased proportion of apoptosis.",
"   </p>",
"   <p>",
"    There have been few studies of apoptosis in the brain following stroke in human patients. However, accumulating evidence suggests that apoptosis is involved [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/24-27\">",
"     24-27",
"    </a>",
"    ], as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a neuropathology study that compared specimens from 27 patients who had cerebral infarction with specimens from rat brains subjected to experimental transient forebrain ischemia, the patterns of cell death were similar in human and animal brain tissue and included both morphologic and histochemical findings typical of apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/24\">",
"       24",
"      </a>",
"      ]. In the human stroke specimens, apoptosis was apparent during the subacute stage, but was not seen in acute or chronic stages.",
"     </li>",
"     <li>",
"      In another neuropathology report that compared 13 cases of fatal ischemic stroke with three patients who died of non-neurologic causes, histochemical and morphologic changes indicative of apoptosis were seen in cells throughout the brain of both patients and controls [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/27\">",
"       27",
"      </a>",
"      ]. The morphologic changes were more advanced in the peri-infarct region and infarct core of the patients with stroke. Apoptotic cells were located primarily within the peri-infarct region, consisting of up to 26 percent of all cells. Increased ischemic damage and neuronal necrosis was associated with a decrease in the percentage of apoptotic cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The deciding factor in determining whether cells undergo necrosis or apoptosis seems to be the level of energy available in the form of ATP, which is required for formation of the apoptosome. Apoptosis is unable to proceed in its absence. When energy levels are limiting, cell death therefore occurs by necrosis rather than apoptosis. The role of ATP in the mechanism of cell death has been investigated primarily using cell culture models. Cultured neurons depend on the presence of serum in the culture medium for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/22\">",
"     22",
"    </a>",
"    ]. If the serum is removed, the cells die by necrosis. In serum-free media with added glucose, however, the cells die by apoptosis.",
"   </p>",
"   <p>",
"    Levels of ATP in the brain are decreased during stroke due to the lack of glucose and oxygen required for normal cellular metabolism. Glucose metabolism is decreased by about 50 percent in both global and focal ischemia models of stroke. As a consequence, ATP levels may fall to 10 percent of normal in global models or 25 percent in the infarct core in focal ischemia models. ATP levels in the penumbra, however, only drop to 50 percent to 70 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ATP levels in the brain may also be decreased by mitochondrial damage or failure, activity of DNA repair enzymes, such as PARP, and neuronal depolarization related to glutamate excitotoxicity. In stroke, therefore, low levels of ATP within the core infarct are insufficient to support apoptosis, and cell death occurs by necrosis. In the penumbra, ATP levels are sufficient enough that cell death by apoptosis can occur. As the duration of ischemia increases, however, ATP levels are eventually depleted and the proportion of cells that undergo necrosis is increased, with a decrease in the number of apoptotic cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1223338\">",
"    <span class=\"h2\">",
"     Loss of brain structural integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral ischemia and infarction leads to loss of the structural integrity of the affected brain tissue and blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/6\">",
"     6",
"    </a>",
"    ]. This process of tissue destruction and neurovascular disruption is mediated in part by the release of various proteases, particularly the matrix metalloproteases (MMP) that degrade collagens and laminins in the basal lamina [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/7,29\">",
"     7,29",
"    </a>",
"    ]. The loss of vascular integrity leads to a breakdown of the blood-brain-barrier and development of cerebral edema. Catastrophic failure of vascular integrity is postulated to cause hemorrhagic conversion of ischemic infarction by allowing extravasation of blood constituents into the brain parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1223360\">",
"    <span class=\"h3\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral edema complicating stroke can cause secondary damage by several mechanisms, including increased intracranial pressure, which may decrease cerebral blood flow, and mass effect causing displacement of brain tissue from one compartment to another (ie, herniation), a process that can be life-threatening.",
"   </p>",
"   <p>",
"    Two types of cerebral edema can occur as a consequence of ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/2,6,30,31\">",
"     2,6,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytotoxic edema is caused by the failure of ATP-dependent transport of sodium and calcium ions across the cell membrane. The result is accumulation of water and swelling of the cellular elements of the brain, including neurons, glia, and endothelial cells.",
"     </li>",
"     <li>",
"      Vasogenic edema is caused by increased permeability or breakdown of the brain vascular endothelial cells that constitute the blood-brain barrier [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/32\">",
"       32",
"      </a>",
"      ]. This allows proteins and other macromolecules to enter the extracellular space, resulting in increased extracellular fluid volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Roughly 10 percent of ischemic strokes are classified as malignant or massive because of the presence of space-occupying cerebral edema that is severe enough to produce elevated intracranial pressure and brain herniation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/569?source=see_link&amp;anchor=H2#H2\">",
"     \"Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction\", section on 'Clinical features of malignant hemispheric infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21816556\">",
"    <span class=\"h1\">",
"     GENETICS OF STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the known risk factors for stroke are variable traits influenced by multiple genes, making it difficult to sort out the genetics behind them. The study of stroke genetics is also impaired by interactions between different risk factors that modulate their effects. It is widely accepted, however, that there is a genetic component to stroke that can lead to increased or decreased risk. Outside of the monogenic disorders discussed below, it is probable that many alleles with small effect sizes contribute to the risk of ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/33\">",
"     33",
"    </a>",
"    ]. Much of the evidence for this comes from studies of twins and from families with a history of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Earlier studies of twins have been troubled by low sample numbers and poor classification of stroke type [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/34\">",
"       34",
"      </a>",
"      ]. However, these studies indicate that stroke-related death in one sibling is associated with a higher risk of stroke-related death in the other sibling among monozygotic (identical) twins versus dizygotic (fraternal) twins. This observation suggests that genetic factors shared by the monozygotic twins played a role in their strokes. As an example, in one of the larger twin studies that evaluated 990 same-sex twin pairs, stroke death affecting both siblings was twice as likely among monozygotic twin pairs compared with dizygotic twin pairs (10 versus 5 percent), and the difference was statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A family history of stroke is associated with an increased risk of stroke among the offspring [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/36\">",
"       36",
"      </a>",
"      ]. This has been observed for offspring with maternal and paternal histories of stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/34\">",
"       34",
"      </a>",
"      ], and among individuals having a sibling with a prior stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Familial inheritance is often studied in isolated populations, such as those of Iceland, where it is easier to detect an increased risk of stroke caused by a mutation within a single gene. However, the data from these studies has often been inconsistent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 296 Icelandic families, a four-marker haplotype spanning the ALOX5AP gene was associated with a twofold greater risk of stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/38\">",
"       38",
"      </a>",
"      ]. However, a meta-analysis with 5194 stroke cases and 4566 controls found a nonsignificant association with two different haplotypes of ALOX5AP and stroke risk [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another susceptibility locus for stroke in Icelandic populations is the gene encoding phosphodiesterase 4D (PDE4D). However, a meta-analysis of 16 studies with over 5200 cases and 6000 controls found no association between PDE4D and ischemic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/40\">",
"       40",
"      </a>",
"      ], and a Bayesian meta-analysis with greater statistical power also found no association [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of genome-wide association studies (GWAS) that analyzed data from over 12,000 subjects of European ancestry with ischemic stroke and 60,000 controls identified three loci (PITX2, ZFHX3, and HDAC9) with genome-wide significance for ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/42\">",
"     42",
"    </a>",
"    ]. Importantly, each locus was associated with a specific stroke subtype:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PITX2 and ZFHX3, previously identified as risk factors for atrial fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/43-45\">",
"       43-45",
"      </a>",
"      ], were associated with cardioembolic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HDAC9 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/45\">",
"       45",
"      </a>",
"      ] was associated with large vessel ischemic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 9P21 locus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/46\">",
"     46",
"    </a>",
"    ] was also associated with large vessel ischemic stroke in the 2012 meta-analysis but did not reach statistical significance at the genome-wide level [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/42\">",
"     42",
"    </a>",
"    ]. The association of PRKCH as a risk factor for small vessel stroke, previously demonstrated in a Japanese population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/47\">",
"     47",
"    </a>",
"    ], could not be confirmed in the meta-analysis because the locus is monomorphic in those of European ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethnic differences may also contribute to stroke risk. Although differences in lifestyle may be partly responsible for increased or decreased likelihood of stroke, genetic factors also play a role. As an example, individuals of African descent have a significantly higher rate of stroke than Caucasians, even after adjusting for differences in nongenetic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/34,48\">",
"     34,48",
"    </a>",
"    ]. This may or may not be related to the increased frequency among African populations of the sickle cell trait, which is a known cause of stroke due to the obstruction of small blood vessels by abnormal red blood cells. Even in monogenic disorders such as sickle cell disease, multiple genes may interact to modify risk. In a study of 1398 individuals with sickle cell anemia, 12 genes were found to interact with the mutated hemoglobin and modulate the risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86785844\">",
"    <span class=\"h2\">",
"     Monogenic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of monogenic syndromes are associated with an increased risk of ischemic stroke, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marfan syndrome and Ehlers-Danlos syndrome, which predispose to cervical artery dissection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=see_link&amp;anchor=H163601524#H163601524\">",
"       \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\", section on 'Predisposing conditions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Familial moyamoya disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link&amp;anchor=H2#H2\">",
"       \"Moyamoya disease: Etiology, clinical features, and diagnosis\", section on 'Etiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fabry disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=see_link\">",
"       \"Neurologic manifestations of Fabry disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pseudoxanthoma elasticum (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7285?source=see_link&amp;anchor=H12#H12\">",
"       \"Metabolic and inherited diseases affecting the skin\", section on 'Pseudoxanthoma elasticum'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Homocystinuria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H14#H14\">",
"       \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'Metabolic disorders'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Menkes disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H14#H14\">",
"       \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'Metabolic disorders'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebral autosomal dominant arteriopathy with subcortical infarctions and leukoencephalopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=see_link\">",
"       \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebral autosomal recessive arteriopathy with subcortical infarctions and leukoencephalopathy (CARASIL) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sickle cell disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H15#H15\">",
"       \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'MELAS and disorders causing metabolic stroke'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to note that all of these conditions together account for only a small percentage of ischemic strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/249/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21816563\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Under normal conditions, the rate of cerebral blood flow is primarily determined by the amount of resistance within cerebral blood vessels. Dilation of vessels leads to an increased volume of blood in the brain and increased cerebral blood flow, whereas constriction of vessels has the opposite effect. Cerebral blood flow is also determined by variation in the cerebral perfusion pressure. (See",
"      <a class=\"local\" href=\"#H1222833\">",
"       'Cerebral autoregulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The brain is exquisitely sensitive to even short durations of ischemia. Multiple mechanisms are involved in tissue damage that results from brain ischemia. (See",
"      <a class=\"local\" href=\"#H21816535\">",
"       'Consequences of reduction in blood flow during stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain ischemia initiates a cascade of events that eventually lead to cell death, including depletion of ATP, changes in ionic concentrations of sodium, potassium, and calcium, increased lactate, acidosis, accumulation of oxygen free radicals, intracellular accumulation of water, and activation of proteolytic processes. (See",
"      <a class=\"local\" href=\"#H21816542\">",
"       'Mechanisms of ischemic cell injury and death'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Cell death following cerebral ischemia or stroke can occur by either necrosis or by apoptosis. Low levels of ATP within the core infarct are insufficient to support apoptosis, and cell death occurs by necrosis. In the ischemic penumbra, ATP levels are sufficiently high that cell death by apoptosis can occur. As the duration of ischemia increases, however, ATP levels are eventually depleted and the proportion of cells that undergo necrosis is increased. (See",
"      <a class=\"local\" href=\"#H21816549\">",
"       'Necrosis and apoptosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/1\">",
"      Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan LR. Basic pathology, anatomy, and pathophysiology of stroke. In: Caplan's Stroke: A Clinical Approach, 4th ed, Saunders Elsevier, Philadelphia 2009. p.22.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/3\">",
"      Markus HS. Cerebral perfusion and stroke. J Neurol Neurosurg Psychiatry 2004; 75:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/4\">",
"      Atkins ER, Brodie FG, Rafelt SE, et al. Dynamic cerebral autoregulation is compromised acutely following mild ischaemic stroke but not transient ischaemic attack. Cerebrovasc Dis 2010; 29:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/5\">",
"      Aries MJ, Elting JW, De Keyser J, et al. Cerebral autoregulation in stroke: a review of transcranial Doppler studies. Stroke 2010; 41:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/6\">",
"      Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology 2010; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/7\">",
"      Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008; 55:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/8\">",
"      Douen AG, Akiyama K, Hogan MJ, et al. Preconditioning with cortical spreading depression decreases intraischemic cerebral glutamate levels and down-regulates excitatory amino acid transporters EAAT1 and EAAT2 from rat cerebal cortex plasma membranes. J Neurochem 2000; 75:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/9\">",
"      Szatkowski M, Barbour B, Attwell D. Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature 1990; 348:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/10\">",
"      Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 2000; 403:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/11\">",
"      Grewer C, Gameiro A, Zhang Z, et al. Glutamate forward and reverse transport: from molecular mechanism to transporter-mediated release after ischemia. IUBMB Life 2008; 60:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/12\">",
"      Nandagopal K, Dawson TM, Dawson VL. Critical role for nitric oxide signaling in cardiac and neuronal ischemic preconditioning and tolerance. J Pharmacol Exp Ther 2001; 297:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/13\">",
"      Lu GW, Liu HY. Downregulation of nitric oxide in the brain of mice during their hypoxic preconditioning. J Appl Physiol 2001; 91:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/14\">",
"      Bola&ntilde;os JP, Almeida A. Roles of nitric oxide in brain hypoxia-ischemia. Biochim Biophys Acta 1999; 1411:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/15\">",
"      Love S. Oxidative stress in brain ischemia. Brain Pathol 1999; 9:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/16\">",
"      Mattson MP, Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med 2003; 9:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/17\">",
"      Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/18\">",
"      Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol 2012; 69:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/19\">",
"      del Zoppo GJ, Becker KJ, Hallenbeck JM. Inflammation after stroke: is it harmful? Arch Neurol 2001; 58:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/20\">",
"      Macrez R, Ali C, Toutirais O, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol 2011; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/21\">",
"      Snider BJ, Gottron FJ, Choi DW. Apoptosis and necrosis in cerebrovascular disease. Ann N Y Acad Sci 1999; 893:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/22\">",
"      Ueda H, Fujita R. Cell death mode switch from necrosis to apoptosis in brain. Biol Pharm Bull 2004; 27:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/23\">",
"      Back T, Hemmen T, Sch&uuml;ler OG. Lesion evolution in cerebral ischemia. J Neurol 2004; 251:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/24\">",
"      Guglielmo MA, Chan PT, Cortez S, et al. The temporal profile and morphologic features of neuronal death in human stroke resemble those observed in experimental forebrain ischemia: the potential role of apoptosis. Neurol Res 1998; 20:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/25\">",
"      Tarkowski E, Rosengren L, Blomstrand C, et al. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke 1999; 30:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/26\">",
"      Love S, Barber R, Wilcock GK. Neuronal death in brain infarcts in man. Neuropathol Appl Neurobiol 2000; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/27\">",
"      Sairanen T, Karjalainen-Lindsberg ML, Paetau A, et al. Apoptosis dominant in the periinfarct area of human ischaemic stroke--a possible target of antiapoptotic treatments. Brain 2006; 129:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/28\">",
"      Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/29\">",
"      Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/30\">",
"      Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007; 6:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/31\">",
"      Klatzo I. Pathophysiological aspects of brain edema. Acta Neuropathol 1987; 72:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/32\">",
"      Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42:3323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/33\">",
"      Matarin M, Singleton A, Hardy J, Meschia J. The genetics of ischaemic stroke. J Intern Med 2010; 267:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/34\">",
"      Carr FJ, McBride MW, Carswell HV, et al. Genetic aspects of stroke: human and experimental studies. J Cereb Blood Flow Metab 2002; 22:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/35\">",
"      Bak S, Gaist D, Sindrup SH, et al. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke 2002; 33:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/36\">",
"      Seshadri S, Beiser A, Pikula A, et al. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation 2010; 121:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/37\">",
"      Kasiman K, Lundholm C, Sandin S, et al. Familial effects on ischemic stroke: the role of sibling kinship, sex, and age of onset. Circ Cardiovasc Genet 2012; 5:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/38\">",
"      Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/39\">",
"      Zintzaras E, Rodopoulou P, Sakellaridis N. Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis. Am J Epidemiol 2009; 169:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/40\">",
"      Bevan S, Dichgans M, Gschwendtner A, et al. Variation in the PDE4D gene and ischemic stroke risk: a systematic review and meta-analysis on 5200 cases and 6600 controls. Stroke 2008; 39:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/41\">",
"      Newcombe PJ, Verzilli C, Casas JP, et al. Multilocus Bayesian meta-analysis of gene-disease associations. Am J Hum Genet 2009; 84:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/42\">",
"      Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012; 11:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/43\">",
"      Damani SB, Topol EJ. Molecular genetics of atrial fibrillation. Genome Med 2009; 1:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/44\">",
"      Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009; 41:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/45\">",
"      International Stroke Genetics Consortium (ISGC), Wellcome Trust Case Control Consortium 2 (WTCCC2), Bellenguez C, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 2012; 44:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/46\">",
"      Gschwendtner A, Bevan S, Cole JW, et al. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol 2009; 65:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/47\">",
"      Kubo M, Hata J, Ninomiya T, et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet 2007; 39:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/48\">",
"      Rastenyte D, Tuomilehto J, Sarti C. Genetics of stroke--a review. J Neurol Sci 1998; 153:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/49\">",
"      Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/50\">",
"      Ballabio E, Bersano A, Bresolin N, Candelise L. Monogenic vessel diseases related to ischemic stroke: a clinical approach. J Cereb Blood Flow Metab 2007; 27:1649.",
"     </a>",
"    </li>",
"    <li>",
"     Onodera O, Nozaki H, Fukutake T. CARASIL. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK32533/ (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/52\">",
"      Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/53\">",
"      Ophoff RA, DeYoung J, Service SK, et al. Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet 2001; 69:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/249/abstract/54\">",
"      Lanktree MB, Dichgans M, Hegele RA. Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke 2010; 41:825.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14085 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_249=[""].join("\n");
var outline_f0_15_249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21816563\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21816440\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21816470\">",
"      STROKE SUBTYPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1222833\">",
"      CEREBRAL AUTOREGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1222840\">",
"      Cerebral autoregulation during stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21816535\">",
"      CONSEQUENCES OF REDUCTION IN BLOOD FLOW DURING STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21816542\">",
"      Mechanisms of ischemic cell injury and death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21816549\">",
"      - Necrosis and apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1223338\">",
"      Loss of brain structural integrity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1223360\">",
"      - Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21816556\">",
"      GENETICS OF STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86785844\">",
"      Monogenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21816563\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14085|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/18/17698\" title=\"figure 1\">",
"      Arterial dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/22/23918\" title=\"figure 2\">",
"      Cerebral autoregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/46/10990\" title=\"figure 3\">",
"      Effects of decreased cerebral blood flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/28/3531\" title=\"table 1\">",
"      TOAST classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=related_link\">",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromuscular dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/569?source=related_link\">",
"      Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7285?source=related_link\">",
"      Metabolic and inherited diseases affecting the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=related_link\">",
"      Neurologic manifestations of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_15_250="Syndromes with craniofacial abnormalities";
var content_f0_15_250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Syndromes with craniofacial abnormalities",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/250/contributors\">",
"     Edward P Buchanan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/250/contributors\">",
"     Patrick Cole, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/250/contributors\">",
"     Larry H Hollier, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/250/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/250/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/250/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/15/250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/15/250/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/15/250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interruption of normal embryologic growth and differentiation of the face and skull results in a wide variety of craniofacial abnormalities. Craniofacial surgery, which consists of reconstruction of the cranial vault",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    facial skeleton, with or without simultaneous soft-tissue reconstruction, can be performed when these deformities interfere with physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mental well-being.",
"   </p>",
"   <p>",
"    Specific syndromes in which craniofacial abnormalities are the primary feature will be reviewed here. The pathogenesis, diagnosis, and surgical management of craniosynostosis, a subset of craniofacial anomalies, and syndromes in which craniosynostosis is a primary abnormality, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=see_link\">",
"     \"Overview of craniosynostosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRANIOFACIAL MICROSOMIA (CFM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniofacial microsomia (CFM), also referred to as hemifacial microsomia, oculo-auriculo-vertebral spectrum, or first and second branchial arch syndrome, is a sporadically acquired association of anomalies that results from a defect in development of the first and second branchial arches (",
"    <a class=\"graphic graphic_figure graphicRef76109 \" href=\"UTD.htm?36/40/37504\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69339 \" href=\"UTD.htm?7/16/7428\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It is sometimes associated with vertebral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ocular anomalies. Goldenhar syndrome appears to be part of this spectrum (MIM #164210) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The disorder occurs in approximately 1 in 5500 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/6\">",
"     6",
"    </a>",
"    ]. It is typically sporadic, but [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/7\">",
"     7",
"    </a>",
"    ] autosomal dominant inheritance have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism underlying craniofacial microsomia is uncertain. A vascular insult to the developing branchial arches is the most widely accepted explanation. In an animal model, hemorrhage induced in the region of the first and second branchial arches produced the characteristic facial features; the degree of abnormality was proportional to the size of the hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features of CFM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stigmata of this disorder are indicated by the acronym OMENS, for",
"    <strong>",
"     o",
"    </strong>",
"    rbit,",
"    <strong>",
"     m",
"    </strong>",
"    andible,",
"    <strong>",
"     e",
"    </strong>",
"    ar, facial",
"    <strong>",
"     n",
"    </strong>",
"    erve,",
"    <strong>",
"     s",
"    </strong>",
"    oft tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Orbital distortion is typically present, as is mandibular hypoplasia. Ear anomalies include microtia, accessory preauricular tags",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pits, and middle ear defects with hearing impairment (",
"    <a class=\"graphic graphic_picture graphicRef57724 \" href=\"UTD.htm?43/2/44067\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/2\">",
"     2",
"    </a>",
"    ]. Facial nerve involvement leads to hypoplasia of the facial muscles. Soft tissue deficiency, such as profound hypoplasia or absence of the parotid gland and masticatory muscles (temporalis, masseter) may be present.",
"   </p>",
"   <p>",
"    The defects are unilateral in 85 to 90 percent of cases. In these cases, the right side predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/2\">",
"     2",
"    </a>",
"    ]. The abnormalities occur in variable combinations and range in extent from imperceptible to severe.",
"   </p>",
"   <p>",
"    The mandibular abnormalities are described using the Pruzansky classification (",
"    <a class=\"graphic graphic_figure graphicRef81249 \" href=\"UTD.htm?11/35/11839\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71316 \" href=\"UTD.htm?7/8/7299\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 is characterized by mild hypoplasia of the ramus with little abnormality of the mandibular body.",
"     </li>",
"     <li>",
"      In type 2, the mandible has a small condylar head and ramus. The condyle is flat, the glenoid fossa is poorly developed or absent, and the infratemporal surface assumes a flat contour.",
"     </li>",
"     <li>",
"      In type 3, the temporomandibular joint fails to form and the ramus may exist as a thin bony lamina or may be completely absent. The increasing degree of mandibular hypoplasia is associated with increased difficulty with endotracheal intubation for anesthesia and surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bony abnormalities include a decreased maxillary height on the affected side and an occlusal cant, which is defined as rotation of the occlusal plane (a plane passing through the biting surface of the teeth) in the sagittal view [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/15\">",
"     15",
"    </a>",
"    ]. As a general guide, each degree of rotation of the occlusal plane results in a 0.5 mm change in the dental occlusal relationship. This rotation occurs in all types of HFM, with increasing severity from type 1 to type 3. Occlusal cant can be demonstrated clinically by having the child bite down on a tongue depressor to identify any angulation (",
"    <a class=\"graphic graphic_figure graphicRef80119 \" href=\"UTD.htm?36/36/37454\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The zygomatic arch is frequently hypoplastic and the distance between the lateral orbit and the tragus of the ear is decreased. Cleft palate occurs in 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Auricular abnormalities are described using the OMENS+ classification [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 1 describes an external ear that is small but contains all of its components; the auditory canal is not affected.",
"     </li>",
"     <li>",
"      A grade 2 abnormality is characterized by a vertical auricular remnant and complete atresia of the external auditory canal.",
"     </li>",
"     <li>",
"      The most severe deformity is grade 3, in which there is a limited remnant of the ear lobe. Hearing does not correlate with the extent of external ear abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study reviewed the clinical features of 121 patients with HFM [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/16\">",
"     16",
"    </a>",
"    ]. Extracraniofacial anomalies occurred in 55 percent and ranged from one anomaly (13 percent) to multiple affected organ systems (42 percent). No gender or side predominance was detected. Central nervous system, cardiac, and skeletal anomalies each occurred in more than 10 percent of cases; pulmonary, gastrointestinal, and renal deformities were less common. The majority of the heart defects involved the outflow tract or septum. The increased frequency of cardiac anomalies in this condition suggests that abnormal development of neural crest may result in both HFM and conotruncal defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgery for CFM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with HFM do not require surgical correction; this is usually reserved for severe cases. Surgical correction of craniofacial microsomia is usually performed in stages [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/18\">",
"     18",
"    </a>",
"    ]. Preauricular skin tags are typically excised before the child is two years old. This is often comforting to the parents, who see steps being taken to remedy their child's problem. Cranial remodeling may be required at approximately 8 to 12 months of age if the craniofacial abnormality is severe and orbital dystopia (malalignment of the orbits) is present. Surgical reconstruction of the oral commissure is performed before two years of age in patients with HFM.",
"   </p>",
"   <p>",
"    Distraction osteogenesis of the mandible can be used to correct severe mandibular hypoplasia with airway compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Children with a Pruzansky type 1 mandibular deformity are followed clinically from two to six years of age. Type 2 abnormalities respond favorably to distraction osteogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/21\">",
"     21",
"    </a>",
"    ]. The more severe type 3 deformities require reconstruction with a costochondral rib graft. There is still significant debate regarding the optimal timing to perform distraction osteogenesis. It has been postulated that by normalizing dimensions at a younger age, the maxilla and overlying soft tissue may have longer time to develop with a balanced &ldquo;functional matrix&rdquo;, thereby improving long-term facial symmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/20\">",
"     20",
"    </a>",
"    ]. However, this hypothesis has yet to be confirmed by prospective outcome studies.",
"   </p>",
"   <p>",
"    The data on recurrence of the facial deformity after surgery over time are inconsistent as well. One study, for example, found that facial asymmetry improved significantly after distraction, and despite mild relapse observed during the first year, surgical correction was stable in the later years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/22\">",
"     22",
"    </a>",
"    ]. However, another study found that the facial proportions gradually returned to their original asymmetry after the growth of the patient in those treated with mandibular distraction osteogenesis in early childhood, and this growth was similar to the outcomes in an untreated group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/23\">",
"     23",
"    </a>",
"    ]. While early surgery may have aesthetic and psychologic advantages, some of these patients may require a second procedure once their growth has completed.",
"   </p>",
"   <p>",
"    Orthodontic treatment is started at anywhere from 6 to 14 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/24\">",
"     24",
"    </a>",
"    ], and ear reconstruction is performed at approximately eight years. Ears can be fashioned from rib cartilage and placed under the mastoid skin. Alternatively, an osseointegrated post can be surgically implanted in the mastoid area, allowing a prosthetic ear to be firmly attached. The ear is displaced in a downward and anterior direction to accommodate future growth, and calvarial bone grafts may be needed to reconstruct the appropriate topography [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Craniofacial growth is completed at approximately 14 to 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/26\">",
"     26",
"    </a>",
"    ]. Further surgical intervention is initiated at that time. Maxillary repositioning (Le Fort 1), mandibular advancement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/27\">",
"     27",
"    </a>",
"    ], and soft tissue augmentation in the form of microsurgical flap transfers and fat grafting are used to improve both form and function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREACHER COLLINS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treacher Collins syndrome (TCS), also called mandibulofacial dysostosis, is an autosomal dominant disorder of craniofacial development with a variable degree of penetrance. It occurs with a frequency of 1 in 25,000 to 50,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetics and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of cases, abnormal bilateral first and second branchial arch development is due to mutations in the gene TCOF1 (Treacher Collins syndrome 1, MIM #154500) located on chromosome 5 (5q31.3-q33.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. This gene encodes the protein treacle that plays an essential role in rRNA transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/35\">",
"     35",
"    </a>",
"    ] and ribosome biogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/36\">",
"     36",
"    </a>",
"    ] and shows peak expression in the neural crest cells of the branchial arches [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/32,37\">",
"     32,37",
"    </a>",
"    ]. Missense mutations in the POLR1D gene located at 13q12.2 (Treacher Collins syndrome 2, MIM #613717). Treacher Collins type I and II are autosomal dominant. A third type, Treacher Collins syndrome 3 is autosomal recessive and caused by compound heterozygous mutations in the POLR1C gene located at 6p22.3 (MIM #248390) that encode subunits of RNA polymerases I and III have been detected in individuals with Treacher Collins syndrome who are negative for TCOF1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/38\">",
"     38",
"    </a>",
"    ]. The underlying genetic defect is still unknown in about 10 percent of patients with TCS.",
"   </p>",
"   <p>",
"    Macroscopically, craniofacial tissues such as cartilage, bone, and connective tissues fail to develop correctly as a direct result of neural crest cell dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/39\">",
"     39",
"    </a>",
"    ]. One hypothesis posits that significant craniofacial malformations largely arise through defects in the formation, migration, or differentiation of this particular cell population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to Tessier's classification of clefts, this syndrome consists of a cleft between the 6 through 8 positions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/41\">",
"     41",
"    </a>",
"    ]. TCS may result from insufficient mesodermal penetration affecting soft tissue thickness and leading to aplasia or hypoplasia of maxilla and zygoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44581?source=see_link&amp;anchor=H5#H5\">",
"     \"Facial clefts and holoprosencephaly\", section on 'Classification of clefts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features of TCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients have malar hypoplasia and a cleft in the zygoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/29,42\">",
"     29,42",
"    </a>",
"    ]. The eyes have an antimongoloid slant with colobomas (eyelid notch) along the lateral one-third of the lower lid. Lashes are absent from the medial two-thirds of the lower eyelid. The face has a convex profile with a retrusive chin and jaw, which is associated with a class 2 malocclusion (overbite).",
"   </p>",
"   <p>",
"    External ear abnormalities are common. Profound sensorineural hearing loss is common in severe cases, and children must be fitted early with bone-conducting hearing aids to facilitate development of normal speech. Cleft lip and palate and choanal atresia may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hearing impairment in children\", section on 'Bone conduction hearing devices'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=see_link\">",
"     \"Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital anomalies of the nose\", section on 'Choanal atresia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The craniofacial abnormalities can result in airway narrowing and respiratory compromise. As a result, affected patients may require prone positioning or surgery to maintain a patent airway. Weak, uncoordinated swallowing may necessitate gavage feedings or placement of a gastrostomy tube. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Surgery for TCS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgery for TCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with airway and feeding difficulties may require surgery during the first couple years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. These procedures may include tongue-lip adhesion (glossopexy), distraction osteogenesis of the mandible, tracheostomy, correction of cleft lip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palate and choanal atresia, and gastrostomy tube placement.",
"   </p>",
"   <p>",
"    Surgical correction of the facial abnormalities in patients with severe Treacher Collins syndrome is initiated at approximately seven years of age when a significant degree of facial growth has occurred. The zygomatic contour is improved using split calvarial bone grafts or iliac crest grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/44,46-48\">",
"     44,46-48",
"    </a>",
"    ]. Lower eyelid colobomas are treated with a layered approach to reconstruction, using mucosal grafts to replace missing lining in conjunction with a lateral canthopexy.",
"   </p>",
"   <p>",
"    Surgical correction of the mandible is undertaken at 13 to 16 years of age as the jaw reaches dental and skeletal maturity. In the presence of a functioning temporomandibular joint (TMJ), the preferred treatment is ramus osteotomies and orthodontic manipulation. If the TMJ is absent, a costochondral graft is placed at 6 to 10 years of age and followed up with orthognathic surgery in adolescence. Bilateral distraction osteogenesis of the mandible is also used in an attempt to correct the mandibular hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/43\">",
"     43",
"    </a>",
"    ]. Finally, the contour of the facial soft tissues generally requires correction at a later stage when the patient has achieved facial skeletal maturity. The use of microsurgical free flap transfer has improved correction of facial soft tissue contours [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in facial appearance has positive psychosocial and social influences. In one report, 20 patients with Treacher Collins syndrome (mean age 12.2 years) were studied before and at intervals up to four years after craniofacial reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/50\">",
"     50",
"    </a>",
"    ]. Although intellectual ability was unchanged, appearance, self-esteem, and adaptive function improved. The improvement peaked at the one year postoperative assessment and subsequently leveled off.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ROBIN SEQUENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Robin sequence, also known as Pierre Robin sequence and Pierre Robin syndrome, is a condition with multiple causes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Most cases are thought to result from hypoplasia of the mandible that occurs before the ninth week of development. Prior to the eighth week, the tongue is interposed between the developing palatal shelves. In the normal course of development, the tongue is drawn down during the tenth and eleventh weeks, allowing fusion of the palatal shelves. In the Robin sequence, hypoplasia of the mandible results in posterior displacement of the tongue, preventing palatal closure and producing a cleft palate. The etiology of Robin sequence is uncertain; possible mechanisms include genetic disorders, oligohydramnios (which may limit chin growth), myotonia, or connective tissue disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link&amp;anchor=H5#H5\">",
"     \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Robin sequence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Robin sequence often is an isolated abnormality. However, some cases (37 percent in one series of 74 patients) occur as part of a syndrome with multiple malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/53\">",
"     53",
"    </a>",
"    ]. One-third of the patients with associated malformations had Stickler or velocardiofacial syndromes. Some cases of Robin sequence may thus result from developmental misexpression of SOX9 due to disruption of very-long-range-cis regulatory elements [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/54\">",
"     54",
"    </a>",
"    ]. Ophthalmologic examination and fluorescent in situ hybridization study for chromosome 22 deletion should be performed on patients with Robin sequence because of the association with Stickler syndrome and velocardiofacial syndromes. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Stickler and Marshall syndromes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Velocardiofacial (Shprintzen) syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical features of Robin sequence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of Robin sequence are micrognathia, glossoptosis, and cleft palate (",
"    <a class=\"graphic graphic_picture graphicRef68928 \" href=\"UTD.htm?30/48/31491\">",
"     picture 2",
"    </a>",
"    ). The tongue tends to prolapse backward, leading to airway obstruction that can be life-threatening. Respiratory compromise can lead to hypoxia, cardiopulmonary arrest, pulmonary hypertension, and failure to thrive. Feeding problems are common [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid facial growth that occurs from 3 to 12 months of age leads to resolution of airway problems in a majority of cases. The mortality associated with Robin sequence is generally related to airway compromise, and is higher when associated with prematurity. Mortality rates in term infants with Robin sequences range from 1.7 to 11.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/52,55\">",
"     52,55",
"    </a>",
"    ]. However, the reported mortality rate increases to 26 percent when other anomalies are present [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management of Robin sequence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two primary issues in patients with Robin sequence are upper airway obstruction and feeding difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/52,56\">",
"     52,56",
"    </a>",
"    ]. Affected patients should be monitored to detect apnea and airway obstruction. Prone positioning is indicated, especially during feeding, to minimize airway obstruction. A rubber tube placed through the nose (nasopharyngeal trumpet) may protect the airway while awaiting compensatory growth. More invasive temporizing procedures are needed if respiratory obstruction is unresponsive to conservative measures.",
"   </p>",
"   <p>",
"    Nonsurgical options for treatment of upper airway obstruction include noninvasive respiratory support (NRS) and a nasopharyngeal airway (NPA). Surgical options include mandibular distraction osteogenesis and glossopexy. Cases of airway obstruction that are refractory to these measures may require a tracheostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=see_link\">",
"     \"Overview of tracheostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive respiratory support (NRS) uses continuous positive airway pressure or noninvasive positive pressure ventilation to correct the airway obstruction. In a series of 81 patients over 10 years, 63 percent were treated with positioning and medical treatment, 12 percent required temporary intubation and positioning, 16 percent required tracheotomy, and 9 percent were treated with NRS [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/57\">",
"       57",
"      </a>",
"      ]. NRS was shown to improve breathing patterns, respiratory efforts, and transcutaneous carbon dioxide pressures in infants with severe upper airway obstruction due to Robin sequence. None of the seven infants treated with NRS required tracheostomy and six out of seven were able to discontinue nutritional support.",
"     </li>",
"     <li>",
"      A second nonsurgical option to relieve airway obstruction is placement of a nasopharyngeal airway (NPA) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/58-60\">",
"       58-60",
"      </a>",
"      ]. Improved oxygen saturation and weight gain has been documented with this method.",
"     </li>",
"     <li>",
"      Distraction of the mandible, in which osteotomy or fracture of the mandible is performed and an external fixator is used to open the oral passage, is the most commonly used surgical procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/61-63\">",
"       61-63",
"      </a>",
"      ]. Distraction has the benefit of affecting permanent change in mandibular size creating adequate space for the tongue. It has allowed many patients to avoid tracheostomy.",
"     </li>",
"     <li>",
"      Historically, glossopexy or tongue-lip adhesion, where the tongue is sutured to the lip to prevent retrusion, was the surgical method of choice. The use of glossopexy has decreased in popularity; however, it is associated with decreased morbidity and normalized weight gain and remains a valid alternative [",
"      <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/64,65\">",
"       64,65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NAGER SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nager syndrome, also known as Nager acrofacial dysostosis syndrome, is a rare disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Most cases are sporadic, although both autosomal recessive and autosomal dominant inheritance have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/68\">",
"     68",
"    </a>",
"    ]. Mutations in",
"    <em>",
"     SF3B4",
"    </em>",
"    (splicing factor 3B, subunit 4) leading to haploinsufficiency were identified in 61 percent of affected individuals in one cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <em>",
"     SF3B4",
"    </em>",
"    encodes spliceosome-associated protein 49 kD (SAP49), a subunit of the pre-mRNA spliceosome complex.",
"   </p>",
"   <p>",
"    The craniofacial features of Nager syndrome are similar to those of Treacher Collins. Nager syndrome is distinguished from Treacher Collins by the absence of eyelid colobomas. Severe cleft palate is always present. The palatal defect is unique in that the cleft is wide, but the hard and soft palates are shortened in the anterior-posterior dimension. Characteristic limb anomalies include preaxial deformities such as hypoplasia or agenesis of the radius and thumb [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/70\">",
"     70",
"    </a>",
"    ]. Affected children have short stature. Intelligence is normal, although delays in speech and language development may occur secondary to hearing impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/66,71\">",
"     66,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with Nager syndrome frequently have respiratory and feeding problems that may require gavage feeding or gastrostomy tube placement. The high perinatal mortality rate (approximately 11 percent) is related to respiratory compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management is similar to that for the Robin sequence as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Robin sequence'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BINDER SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binder syndrome, also known as maxillonasal dysplasia, is a very rare disorder of unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/74\">",
"     74",
"    </a>",
"    ]. It is hypothesized that Binder syndrome is the mildest form of chondrodysplasia punctata [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/75\">",
"     75",
"    </a>",
"    ]. Binder syndrome is characterized by a shortened nose with an acute nasolabial angle and a convex upper lip (",
"    <a class=\"graphic graphic_picture graphicRef53807 \" href=\"UTD.htm?16/50/17191\">",
"     picture 3",
"    </a>",
"    ). Class III malocclusion may be present. An underdeveloped frontal sinus and cervicospinal abnormalities occur in 40 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment consists of nasal and maxillary correction, followed by orthodontic rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Depending on the involvement of the malformation, surgical treatment can be limited to reconstruction of the nasal dorsum and apex only, or extend to include maxillary advancement. Grafting to the nasal osteochondral scaffold can be performed in early adolescence; however, osteotomy with maxillary advancement should be reserved until the late teenage years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/79\">",
"     79",
"    </a>",
"    ]. Surgeons have reported the use of bone and cartilage grafts, and a comparison between the two demonstrated that either option is adequate for creating a normal nasolabial angle and tip projection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VELOCARDIOFACIAL (SHPRINTZEN) SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Velocardiofacial syndrome (VCFS), also known as Shprintzen syndrome, is an autosomal dominant disorder caused by a deletion in chromosome 22q11 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. This deletion has also been identified in the majority of patients with DiGeorge sequence and conotruncal anomaly face syndrome, suggesting that these are phenotypic variants of the same disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=see_link\">",
"     \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The deletion occurs in approximately 1 in 4000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/83\">",
"     83",
"    </a>",
"    ] and can be detected by fluorescent in situ hybridization (FISH), multiple ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (array CGH). The deletion occurs 'de novo' in the majority of cases, but approximately 15 percent are inherited from an affected parent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538597#H15538597\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Detecting cytogenetic abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=see_link&amp;anchor=H16722234#H16722234\">",
"     \"Genomic disorders: An overview\", section on 'Detection of genomic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical features of VCFS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients have retrognathia, a long face with a prominent nose [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/84\">",
"     84",
"    </a>",
"    ]. Velopharyngeal incompetence (weak pharyngeal musculature) producing speech abnormalities, such as hypernasal speech is very common. Submucous or overt clefts of the secondary palate can occur. Chronic otitis media is present in 75 percent of cases. Transient neonatal hypocalcemia occurs in 20 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"     \"Neonatal hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital heart defects occur in 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/84\">",
"     84",
"    </a>",
"    ]. The most common are ventricular septal defect (62 percent), right-sided aortic arch (52 percent), and tetralogy of Fallot (21 percent). The carotid arteries frequently follow an anomalous course that may complicate the performance of pharyngeal surgical procedures (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"     \"Vascular rings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link\">",
"     \"Diagnosis and initial management of cyanotic heart disease in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Learning disabilities are frequent and mild intellectual impairment occurs in approximately 40 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H6#H6\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychiatric disorders, primarily schizophrenia and paranoid delusions, develop in 10 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Magnetic resonance imaging studies comparing patients with VCFS and controls have demonstrated structural changes in the temporal lobe, left hippocampal, frontal, and caudate areas that are similar to the alterations of these regions that are seen in patients with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management of VCFS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngeal surgery (pharyngoplasty) is frequently required to treat the nasal air escape that causes abnormal speech [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. High inset of the pharyngeal flap is indicated because of severe, refractory velopharyngeal incompetence. This is technically difficult because of visualization issues; some authors report success with through-and-through dissection of the soft palate to allow direct visualization of flap placement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Removal of the tonsils and adenoids is contraindicated, because they aid in velopharyngeal closure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     STICKLER AND MARSHALL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stickler (also known as hereditary arthroophthalmopathy) and Marshall syndromes are related disorders of connective tissue with overlapping characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. It is unclear whether they are distinct entities or different clinical manifestations of a single syndrome. Most patients have autosomal dominant inheritance, although autosomal recessive forms of Stickler syndrome occur.",
"   </p>",
"   <p>",
"    Mutations of the gene for the alpha-1 chain of type II collagen (COL2A1) located on chromosome 12q13.11-q13.2 cause Stickler syndrome type I (MIM #108300) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/96\">",
"     96",
"    </a>",
"    ]. These mutations result in the abnormal production and assembly of type II collagen, which is a major component of cartilage, vitreous, and nucleus pulposus. Mutations in the COL11A1 gene located at 1p21 that encodes the alpha-1 chain of type XI collagen have been found in patients with Stickler syndrome type II (MIM #604841) or Marshall syndrome (MIM #154780), or with overlapping phenotypes of both [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/97\">",
"     97",
"    </a>",
"    ]. Stickler syndrome type III (MIM #184840) is caused by mutation in the COL11A2 gene located at 6p21.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/98\">",
"     98",
"    </a>",
"    ]. Rare autosomal recessive forms of Stickler syndrome are caused by biallelic mutations in any of the three genes encoding collagen IX (ie, COL9A1, COL9A2, and COL9A3) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of Stickler syndrome include characteristic orofacial and ophthalmologic abnormalities, deafness, and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/94,95,97\">",
"     94,95,97",
"    </a>",
"    ]. Affected patients typically have a flat midface with a depressed nasal bridge, short nose, anteverted nares, and micrognathia. Midline cleft palate can occur, and ranges in severity from a cleft in the soft palate to the Pierre Robin sequence (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Robin sequence'",
"    </a>",
"    above). Abnormal architecture of the vitreous gel is pathognomonic of this disorder, and is usually associated with high myopia. Retinal detachment occurs frequently. Joint hypermobility is present in infancy and decreases with age. Patients typically develop osteoarthritis in the third or fourth decade. Some patients have sensorineural deafness. Mitral valve prolapse may occur.",
"   </p>",
"   <p>",
"    Marshall syndrome has clinical features similar to Stickler syndrome. These include a craniofacial appearance characterized by a flat midface, depressed nasal bridge, short nose, and anteverted nares. Patients have ocular abnormalities (eg, cataracts, myopia), sensorineural hearing loss, and spondyloepiphyseal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/101\">",
"     101",
"    </a>",
"    ]. Anhidrotic ectodermal dysplasia may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H36#H36\">",
"     \"The genodermatoses\", section on 'Anhidrotic ectodermal dysplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link&amp;anchor=H11#H11\">",
"     \"Cataract in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eye findings are usually nonprogressive and are found in neonates. Early ophthalmologic examination is indicated. Treatment of Robin sequence is discussed above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Management of Robin sequence'",
"    </a>",
"    above.) Cleft palate, if present, should be repaired prior to speech production. Surgery is performed earlier in infancy if the airway is unstable. Further surgery for speech competence is often indicated, because of the increased incidence of velopharyngeal insufficiency in these patients. Otolaryngologists should be consulted for auditory concerns. Orthopedic surgery and physical therapy are often involved in patient care for early onset of arthritis, which is most commonly treated with over-the-counter antiinflammatories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VAN DER WOUDE SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Van der Woude syndrome is an autosomal dominant disorder with a high degree of penetration. It is characterized by pits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sinuses in the lower lip and cleft lip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cleft palate [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/103\">",
"     103",
"    </a>",
"    ]. This condition represents 1 percent of cleft lip and palate cases and should be suspected when lower lip pits are present (",
"    <a class=\"graphic graphic_picture graphicRef50289 \" href=\"UTD.htm?13/41/13983\">",
"     picture 4",
"    </a>",
"    ). Identification of this syndrome is important for genetic counseling because of the 50 percent risk of occurrence in the offspring of an affected individual. The syndrome is usually caused by mutations in the IRF6 gene located on chromosome 1q32-41, but another locus has been identified at 1p34 where the candidate gene WDR65 resides [",
"    <a class=\"abstract\" href=\"UTD.htm?0/15/250/abstract/103-106\">",
"     103-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14783287\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interruption of normal embryologic growth and differentiation of the face and skull results in a wide variety of craniofacial abnormalities (",
"      <a class=\"graphic graphic_figure graphicRef76109 \" href=\"UTD.htm?36/40/37504\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef69339 \" href=\"UTD.htm?7/16/7428\">",
"       figure 2",
"      </a>",
"      ). Specific syndromes in which craniofacial abnormalities are the primary feature include hemifacial microsomia, Treacher Collins syndrome, Robin sequence, Nager syndrome, Binder syndrome, Velocardiofacial syndrome, Stickler and Marshall syndromes, and Van der Woude syndrome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The defects in hemifacial microsomia involve the orbit, mandible, ear, facial nerve, soft tissue, and are typically unilateral (",
"      <a class=\"graphic graphic_picture graphicRef57724 \" href=\"UTD.htm?43/2/44067\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Craniofacial microsomia (CFM)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Treacher Collins syndrome have jaw defects, a notch in the lower eyelid at the junction of the inner two-thirds and outer one-third (eyelid colobomas), partially absent lashes on the lower eyelids, and sensorineural hearing loss. Cleft lip and palate and choanal atresia may occur. The craniofacial abnormalities can result in respiratory compromise and feeding difficulties. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treacher Collins syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Robin sequence, also known as Pierre Robin sequence and Pierre Robin syndrome, is a condition with multiple causes. Most cases are thought to result from hypoplasia of the mandible that occurs before the ninth week of development (",
"      <a class=\"graphic graphic_picture graphicRef68928 \" href=\"UTD.htm?30/48/31491\">",
"       picture 2",
"      </a>",
"      ). Some cases occur as part of a syndrome with multiple malformations (eg, Stickler or velocardiofacial syndrome). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Robin sequence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The craniofacial features of Nager syndrome are similar to those of Treacher Collins. Nager syndrome is distinguished from Treacher Collins by the absence of eyelid colobomas. Severe cleft palate is always present. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nager syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Binder syndrome is characterized by a shortened nose with an acute nasolabial angle and a convex upper lip. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Binder syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Velocardiofacial syndrome (VCFS), also known as Shprintzen syndrome, is an autosomal dominant disorder caused by a deletion in chromosome 22q11. This deletion has also been identified in the majority of patients with DiGeorge sequence and conotruncal anomaly face syndrome. Common clinical features include cleft palate, velopharyngeal incompetence (weak pharyngeal musculature) producing speech abnormalities, chronic otitis media, hypotonia, and congenital heart defects. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Velocardiofacial (Shprintzen) syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stickler and Marshall syndromes have similar clinical features, including a craniofacial appearance characterized by a flat midface, depressed nasal bridge, short nose, and anteverted nares. Stickler syndrome is also characterized by abnormal architecture of the vitreous gel and osteoarthritis. However, there is limited information to distinguish the two syndromes aside from clinical manifestations. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Stickler and Marshall syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Van der Woude syndrome is characterized by pits",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sinuses in the lower lip and cleft lip",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cleft palate (",
"      <a class=\"graphic graphic_picture graphicRef50289 \" href=\"UTD.htm?13/41/13983\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Van der Woude syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with airway and feeding difficulties may require surgery during the first couple years of life. The most common surgical procedure used to correct mandibular hypoplasia is that distraction osteogenesis of the mandible. Other surgeries may be performed during early and later childhood for functional reasons, as well as for aesthetic and psychologic reasons. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgery for CFM'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Surgery for TCS'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Management of Robin sequence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Management of VCFS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89678066\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of Samuel Stal, MD. UpToDate wishes to acknowledge his dedicated work on this review and his contributions to its Genetic diseases in children section.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/1\">",
"      Converse JM, Coccaro PJ, Becker M, Wood-Smith D. On hemifacial microsomia. The first and second branchial arch syndrome. Plast Reconstr Surg 1973; 51:268.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Oculo-auriculo-vertebral spectrum (First and second branchial arch syndrome, facio-auriculo-vertebral spectrum, hemifacial microsomia, Goldenhar syndrome). In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.738.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/3\">",
"      Str&ouml;mland K, Miller M, Sj&ouml;green L, et al. Oculo-auriculo-vertebral spectrum: associated anomalies, functional deficits and possible developmental risk factors. Am J Med Genet A 2007; 143A:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/4\">",
"      Skarzyski H, Porowski M, Podskarbi-Fayette R. Treatment of otological features of the oculoauriculovertebral dysplasia (Goldenhar syndrome). Int J Pediatr Otorhinolaryngol 2009; 73:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/5\">",
"      Tuna EB, Orino D, Ogawa K, et al. Craniofacial and dental characteristics of Goldenhar syndrome: a report of two cases. J Oral Sci 2011; 53:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/6\">",
"      Kelberman D, Tyson J, Chandler DC, et al. Hemifacial microsomia: progress in understanding the genetic basis of a complex malformation syndrome. Hum Genet 2001; 109:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/7\">",
"      Ala-Mello S, Siggberg L, Knuutila S, et al. Further evidence for a relationship between the 5p15 chromosome region and the oculoauriculovertebral anomaly. Am J Med Genet A 2008; 146A:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/8\">",
"      Vendramini-Pittoli S, Kokitsu-Nakata NM. Oculoauriculovertebral spectrum: report of nine familial cases with evidence of autosomal dominant inheritance and review of the literature. Clin Dysmorphol 2009; 18:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/9\">",
"      Tasse C, Majewski F, B&ouml;hringer S, et al. A family with autosomal dominant oculo-auriculo-vertebral spectrum. Clin Dysmorphol 2007; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/10\">",
"      Poswillo D. The pathogenesis of the first and second branchial arch syndrome. Oral Surg Oral Med Oral Pathol 1973; 35:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/11\">",
"      Vento AR, LaBrie RA, Mulliken JB. The O.M.E.N.S. classification of hemifacial microsomia. Cleft Palate Craniofac J 1991; 28:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/12\">",
"      Gougoutas AJ, Singh DJ, Low DW, Bartlett SP. Hemifacial microsomia: clinical features and pictographic representations of the OMENS classification system. Plast Reconstr Surg 2007; 120:112e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/13\">",
"      Pruzansky S. Not all dwarfed mandibles are alike. Birth Defects 1969; 5:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/14\">",
"      Nargozian C, Ririe DG, Bennun RD, Mulliken JB. Hemifacial microsomia: anatomical prediction of difficult intubation. Paediatr Anaesth 1999; 9:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/15\">",
"      Padwa BL, Kaiser MO, Kaban LB. Occlusal cant in the frontal plane as a reflection of facial asymmetry. J Oral Maxillofac Surg 1997; 55:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/16\">",
"      Horgan JE, Padwa BL, LaBrie RA, Mulliken JB. OMENS-Plus: analysis of craniofacial and extracraniofacial anomalies in hemifacial microsomia. Cleft Palate Craniofac J 1995; 32:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/17\">",
"      Birgfeld CB, Luquetti DV, Gougoutas AJ, et al. A phenotypic assessment tool for craniofacial microsomia. Plast Reconstr Surg 2011; 127:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/18\">",
"      Converse JM, Horowitz SL, Coccaro PJ, Wood-Smith D. The corrective treatment of the skeletal asymmetry in hemifacial microsomia. Plast Reconstr Surg 1973; 52:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/19\">",
"      McCarthy JG, Schreiber J, Karp N, et al. Lengthening the human mandible by gradual distraction. Plast Reconstr Surg 1992; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/20\">",
"      Hollier LH, Kim JH, Grayson B, McCarthy JG. Mandibular growth after distraction in patients under 48 months of age. Plast Reconstr Surg 1999; 103:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/21\">",
"      Gate&ntilde;o J, Teichgraeber JF, Aguilar E. Distraction osteogenesis: a new surgical technique for use with the multiplanar mandibular distractor. Plast Reconstr Surg 2000; 105:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/22\">",
"      Shetye PR, Grayson BH, Mackool RJ, McCarthy JG. Long-term stability and growth following unilateral mandibular distraction in growing children with craniofacial microsomia. Plast Reconstr Surg 2006; 118:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/23\">",
"      Meazzini MC, Mazzoleni F, Bozzetti A, Brusati R. Comparison of mandibular vertical growth in hemifacial microsomia patients treated with early distraction or not treated: follow up till the completion of growth. J Craniomaxillofac Surg 2012; 40:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/24\">",
"      Meazzini MC, Mazzoleni F, Bozzetti A, Brusati R. Does functional appliance treatment truly improve stability of mandibular vertical distraction osteogenesis in hemifacial microsomia? J Craniomaxillofac Surg 2008; 36:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/25\">",
"      Yamada A, Ueda K, Yorozuya-Shibazaki R. External ear reconstruction in hemifacial microsomia. J Craniofac Surg 2009; 20 Suppl 2:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/26\">",
"      Stahl F, Baccetti T, Franchi L, McNamara JA Jr. Longitudinal growth changes in untreated subjects with Class II Division 1 malocclusion. Am J Orthod Dentofacial Orthop 2008; 134:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/27\">",
"      McCarthy JG. Craniofacial microsomia. A primary or secondary surgical treatment program. Clin Plast Surg 1997; 24:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/28\">",
"      Longaker MT, Siebert JW. Microvascular free-flap correction of severe hemifacial atrophy. Plast Reconstr Surg 1995; 96:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/29\">",
"      Dixon J, Trainor P, Dixon MJ. Treacher Collins syndrome. Orthod Craniofac Res 2007; 10:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/30\">",
"      Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome. The Treacher Collins Syndrome Collaborative Group. Nat Genet 1996; 12:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/31\">",
"      Marsh KL, Dixon J, Dixon MJ. Mutations in the Treacher Collins syndrome gene lead to mislocalization of the nucleolar protein treacle. Hum Mol Genet 1998; 7:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/32\">",
"      Shows KH, Shiang R. Regulation of the mouse Treacher Collins syndrome homolog (Tcof1) promoter through differential repression of constitutive expression. DNA Cell Biol 2008; 27:589.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: Treacher Collins Syndrome. file://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/books/NBK1532/ (Accessed on April 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/34\">",
"      Schlump JU, Stein A, Hehr U, et al. Treacher Collins syndrome: clinical implications for the paediatrician--a new mutation in a severely affected newborn and comparison with three further patients with the same mutation, and review of the literature. Eur J Pediatr 2012; 171:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/35\">",
"      Valdez BC, Henning D, So RB, et al. The Treacher Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor. Proc Natl Acad Sci U S A 2004; 101:10709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/36\">",
"      Dixon J, Jones NC, Sandell LL, et al. Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities. Proc Natl Acad Sci U S A 2006; 103:13403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/37\">",
"      Jones NC, Farlie PG, Minichiello J, Newgreen DF. Detection of an appropriate kinase activity in branchial arches I and II that coincides with peak expression of the Treacher Collins syndrome gene product, treacle. Hum Mol Genet 1999; 8:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/38\">",
"      Dauwerse JG, Dixon J, Seland S, et al. Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome. Nat Genet 2011; 43:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/39\">",
"      Trainor PA. Craniofacial birth defects: The role of neural crest cells in the etiology and pathogenesis of Treacher Collins syndrome and the potential for prevention. Am J Med Genet A 2010; 152A:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/40\">",
"      Su PH, Chen JY, Chen SJ, Yu JS. Treacher Collins syndrome with a de Novo 5-bp deletion in the TCOF1 gene. J Formos Med Assoc 2006; 105:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/41\">",
"      Tessier P. Anatomical classification facial, cranio-facial and latero-facial clefts. J Maxillofac Surg 1976; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: Treacher Collins syndrome. file://www.ncbi.nlm.nih.gov/books/NBK1532/ (Accessed on June 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/43\">",
"      Kobus K, W&oacute;jcicki P. Surgical treatment of Treacher Collins syndrome. Ann Plast Surg 2006; 56:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/44\">",
"      Thompson JT, Anderson PJ, David DJ. Treacher Collins syndrome: protocol management from birth to maturity. J Craniofac Surg 2009; 20:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/45\">",
"      Genecov DG, Barcel&oacute; CR, Steinberg D, et al. Clinical experience with the application of distraction osteogenesis for airway obstruction. J Craniofac Surg 2009; 20 Suppl 2:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/46\">",
"      Tessier P. Autogenous bone grafts taken from the calvarium for facial and cranial applications. Clin Plast Surg 1982; 9:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/47\">",
"      McCarthy JG, Zide BM. The spectrum of calvarial bone grafting: introduction of the vascularized calvarial bone flap. Plast Reconstr Surg 1984; 74:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/48\">",
"      McCarthy JG, Cutting CB, Shaw WW. Vascularized calvarial flaps. Clin Plast Surg 1987; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/49\">",
"      Saadeh PB, Chang CC, Warren SM, et al. Microsurgical correction of facial contour deformities in patients with craniofacial malformations: a 15-year experience. Plast Reconstr Surg 2008; 121:368e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/50\">",
"      Arndt EM, Travis F, Lefebvre A, Munro IR. Psychosocial adjustment of 20 patients with Treacher Collins syndrome before and after reconstructive surgery. Br J Plast Surg 1987; 40:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/51\">",
"      Shprintzen RJ. The implications of the diagnosis of Robin sequence. Cleft Palate Craniofac J 1992; 29:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/52\">",
"      Evans KN, Sie KC, Hopper RA, et al. Robin sequence: from diagnosis to development of an effective management plan. Pediatrics 2011; 127:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/53\">",
"      van den Elzen AP, Semmekrot BA, Bongers EM, et al. Diagnosis and treatment of the Pierre Robin sequence: results of a retrospective clinical study and review of the literature. Eur J Pediatr 2001; 160:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/54\">",
"      Benko S, Fantes JA, Amiel J, et al. Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin sequence. Nat Genet 2009; 41:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/55\">",
"      B&uuml;tow KW, Hoogendijk CF, Zwahlen RA. Pierre Robin sequence: appearances and 25 years of experience with an innovative treatment protocol. J Pediatr Surg 2009; 44:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/56\">",
"      Poets CF, Bacher M. Treatment of upper airway obstruction and feeding problems in Robin-like phenotype. J Pediatr 2011; 159:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/57\">",
"      Leboulanger N, Picard A, Soupre V, et al. Physiologic and clinical benefits of noninvasive ventilation in infants with Pierre Robin sequence. Pediatrics 2010; 126:e1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/58\">",
"      Wagener S, Rayatt SS, Tatman AJ, et al. Management of infants with Pierre Robin sequence. Cleft Palate Craniofac J 2003; 40:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/59\">",
"      Parhizkar N, Saltzman B, Grote K, et al. Nasopharyngeal airway for management of airway obstruction in infants with micrognathia. Cleft Palate Craniofac J 2011; 48:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/60\">",
"      Abel F, Bajaj Y, Wyatt M, Wallis C. The successful use of the nasopharyngeal airway in Pierre Robin sequence: an 11-year experience. Arch Dis Child 2012; 97:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/61\">",
"      Denny AD, Talisman R, Hanson PR, Recinos RF. Mandibular distraction osteogenesis in very young patients to correct airway obstruction. Plast Reconstr Surg 2001; 108:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/62\">",
"      Denny A, Kalantarian B. Mandibular distraction in neonates: a strategy to avoid tracheostomy. Plast Reconstr Surg 2002; 109:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/63\">",
"      Denny AD. Distraction osteogenesis in Pierre Robin neonates with airway obstruction. Clin Plast Surg 2004; 31:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/64\">",
"      Denny AD, Amm CA, Schaefer RB. Outcomes of tongue-lip adhesion for neonatal respiratory distress caused by Pierre Robin sequence. J Craniofac Surg 2004; 15:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/65\">",
"      Cozzi F, Totonelli G, Frediani S, et al. The effect of glossopexy on weight velocity in infants with Pierre Robin syndrome. J Pediatr Surg 2008; 43:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/66\">",
"      NAGER G. [Not Available]. Pract Otorhinolaryngol (Basel) 1948; 10:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/67\">",
"      Hunt JA, Hobar PC. Common craniofacial anomalies: the facial dysostoses. Plast Reconstr Surg 2002; 110:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/68\">",
"      Mackeprang M, Hay S. Cleft lip and palate mortality study. Cleft Palate J 1972; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/69\">",
"      Bernier FP, Caluseriu O, Ng S, et al. Haploinsufficiency of SF3B4, a component of the pre-mRNA spliceosomal complex, causes Nager syndrome. Am J Hum Genet 2012; 90:925.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Nager syndrome (Nager acrofacial dysostosis syndrome). In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.288.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/71\">",
"      Herrmann BW, Karzon R, Molter DW. Otologic and audiologic features of Nager acrofacial dysostosis. Int J Pediatr Otorhinolaryngol 2005; 69:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/72\">",
"      Ho AS, Aleshi P, Cohen SE, et al. Airway management in Nager Syndrome. Int J Pediatr Otorhinolaryngol 2008; 72:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/73\">",
"      G&uuml;rsoy S, Hukki J, Hurmerinta K. Five year follow-up of mandibular distraction osteogenesis on the dentofacial structures of syndromic children. Orthod Craniofac Res 2008; 11:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/74\">",
"      Nedev PK. The Binder syndrome: review of the literature and case report. Int J Pediatr Otorhinolaryngol 2008; 72:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/75\">",
"      Sheffield LJ, Halliday JL, Jensen F. Maxillonasal dysplasia (Binder's syndrome) and chondrodysplasia punctata. J Med Genet 1991; 28:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/76\">",
"      Horswell BB, Holmes AD, Barnett JS, Levant BA. Maxillonasal dysplasia (Binder's syndrome): a critical review and case study. J Oral Maxillofac Surg 1987; 45:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/77\">",
"      Posnick JC. Surgical management of binder syndrome: lessons learned. Aesthetic Plast Surg 2010; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/78\">",
"      Holmes AD, Lee SJ, Greensmith A, et al. Nasal reconstruction for maxillonasal dysplasia. J Craniofac Surg 2010; 21:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/79\">",
"      Kruk-Jeromin J, Antoszewski B. [Binder's syndrome--symptoms and treatment]. Otolaryngol Pol 2006; 60:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/80\">",
"      Gewalli F, Berlanga F, Monasterio FO, Holmstr&ouml;m H. Nasomaxillary reconstruction in Binder syndrome: bone versus cartilage grafts. A long-term intercenter comparison between Sweden and Mexico. J Craniofac Surg 2008; 19:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/81\">",
"      Holmstr&ouml;m H, Gewalli F. Long-term behavior of three different grafts in nasomaxillary reconstruction of binder syndrome: an analysis by digitalized measurements. Plast Reconstr Surg 2008; 122:1524.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: 22q11.2 Deletion Syndrome. file://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/books/NBK1523/?log$=disease_name (Accessed on June 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/83\">",
"      McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore) 2011; 90:1.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Deletion 22q11.2 syndrome (Velo-cardio-facial syndrome, DiGeorge syndrome, Shprintzen syndrome). In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/85\">",
"      Gothelf D, Frisch A, Michaelovsky E, et al. Velo-Cardio-Facial Syndrome. J Ment Health Res Intellect Disabil 2009; 2:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/86\">",
"      Jolin EM, Weller RA, Weller EB. Psychosis in children with velocardiofacial syndrome (22q11.2 deletion syndrome). Curr Psychiatry Rep 2009; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/87\">",
"      Eliez S, Blasey CM, Schmitt EJ, et al. Velocardiofacial syndrome: are structural changes in the temporal and mesial temporal regions related to schizophrenia? Am J Psychiatry 2001; 158:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/88\">",
"      Kates WR, Burnette CP, Bessette BA, et al. Frontal and caudate alterations in velocardiofacial syndrome (deletion at chromosome 22q11.2). J Child Neurol 2004; 19:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/89\">",
"      Swanson EW, Sullivan SR, Ridgway EB, et al. Speech outcomes following pharyngeal flap in patients with velocardiofacial syndrome. Plast Reconstr Surg 2011; 127:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/90\">",
"      Rottgers SA, Ford M, Cray J, et al. An algorithm for application of furlow palatoplasty to the treatment of velocardiofacial syndrome-associated velopharyngeal insufficiency. Ann Plast Surg 2011; 66:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/91\">",
"      Arneja JS, Hettinger P, Gosain AK. Through-and-through dissection of the soft palate for high pharyngeal flap inset: a new technique for the treatment of velopharyngeal incompetence in velocardiofacial syndrome. Plast Reconstr Surg 2008; 122:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/92\">",
"      Finkelstein Y, Zohar Y, Nachmani A, et al. The otolaryngologist and the patient with velocardiofacial syndrome. Arch Otolaryngol Head Neck Surg 1993; 119:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/93\">",
"      Cervelli V, Bottini DJ, Grimaldi M, et al. The Stickler syndrome. A genetic disease with clinical implications for the plastic surgeon. J Plast Reconstr Aesthet Surg 2008; 61:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/94\">",
"      Richards AJ, McNinch A, Martin H, et al. Stickler syndrome and the vitreous phenotype: mutations in COL2A1 and COL11A1. Hum Mutat 2010; 31:E1461.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: Stickler Syndrome. file://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/books/NBK1302/ (Accessed on June 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/96\">",
"      Snead MP, Yates JR. Clinical and Molecular genetics of Stickler syndrome. J Med Genet 1999; 36:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/97\">",
"      Annunen S, K&ouml;rkk&ouml; J, Czarny M, et al. Splicing mutations of 54-bp exons in the COL11A1 gene cause Marshall syndrome, but other mutations cause overlapping Marshall/Stickler phenotypes. Am J Hum Genet 1999; 65:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/98\">",
"      Sirko-Osadsa DA, Murray MA, Scott JA, et al. Stickler syndrome without eye involvement is caused by mutations in COL11A2, the gene encoding the alpha2(XI) chain of type XI collagen. J Pediatr 1998; 132:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/99\">",
"      Baker S, Booth C, Fillman C, et al. A loss of function mutation in the COL9A2 gene causes autosomal recessive Stickler syndrome. Am J Med Genet A 2011; 155A:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/100\">",
"      Nikopoulos K, Schrauwen I, Simon M, et al. Autosomal recessive Stickler syndrome in two families is caused by mutations in the COL9A1 gene. Invest Ophthalmol Vis Sci 2011; 52:4774.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Marshall syndrome. In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.282.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/102\">",
"      Shanske AL, Bogdanow A, Shprintzen RJ, Marion RW. The Marshall syndrome: report of a new family and review of the literature. Am J Med Genet 1997; 70:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/103\">",
"      Koillinen H, Wong FK, Rautio J, et al. Mapping of the second locus for the Van der Woude syndrome to chromosome 1p34. Eur J Hum Genet 2001; 9:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/104\">",
"      Houdayer C, Soupre V, Rosenberg-Bourgin M, et al. Linkage analysis of 5 novel van der Woude syndrome kindreds to 1q32-q41 markers further supports locus homogeneity of the disease trait. Ann Genet 1999; 42:69.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: IRF6-related disorders. file://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/20301581 (Accessed on June 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/15/250/abstract/106\">",
"      Rorick NK, Kinoshita A, Weirather JL, et al. Genomic strategy identifies a missense mutation in WD-repeat domain 65 (WDR65) in an individual with Van der Woude syndrome. Am J Med Genet A 2011; 155A:1314.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2926 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_250=[""].join("\n");
var outline_f0_15_250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14783287\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRANIOFACIAL MICROSOMIA (CFM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features of CFM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgery for CFM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREACHER COLLINS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features of TCS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgery for TCS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ROBIN SEQUENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical features of Robin sequence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management of Robin sequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NAGER SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BINDER SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VELOCARDIOFACIAL (SHPRINTZEN) SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical features of VCFS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management of VCFS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      STICKLER AND MARSHALL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VAN DER WOUDE SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14783287\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89678066\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2926|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/40/37504\" title=\"figure 1\">",
"      First branchial arch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/16/7428\" title=\"figure 2\">",
"      Branchial arch derivatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/35/11839\" title=\"figure 3\">",
"      Pruzansky classification of mandibular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/8/7299\" title=\"figure 4\">",
"      Normal anatomy of the mandible",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/36/37454\" title=\"figure 5\">",
"      Occlusal cant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2926|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/2/44067\" title=\"picture 1\">",
"      Hemifacial microsomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/48/31491\" title=\"picture 2\">",
"      Pierre Robin sequence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/50/17191\" title=\"picture 3\">",
"      Binder syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/41/13983\" title=\"picture 4\">",
"      Congenital lip pits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=related_link\">",
"      Craniosynostosis syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=related_link\">",
"      Diagnosis and initial management of cyanotic heart disease in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=related_link\">",
"      Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44581?source=related_link\">",
"      Facial clefts and holoprosencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=related_link\">",
"      Genomic disorders: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=related_link\">",
"      Neonatal hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=related_link\">",
"      Overview of craniosynostosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_15_251="Impairment and lung function";
var content_f0_15_251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions with impairment not directly related to lung function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumoconiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung cancer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_251=[""].join("\n");
var outline_f0_15_251=null;
var title_f0_15_252="Clinical findings by stage of hypothermia";
var content_f0_15_252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings by stage of hypothermia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Core temperature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Mild",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         32-35&deg;C",
"        </p>",
"        (90-95&deg;F)",
"       </td>",
"       <td>",
"        Shivering but conscious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged capillary refill",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Moderate",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         28-32&deg;C",
"        </p>",
"        (82-90&deg;F)",
"       </td>",
"       <td>",
"        Shivering stops, impaired consciousness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clumsiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confusion or delirium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slurred speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreasing BP",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        Severe",
"       </td>",
"       <td rowspan=\"8\">",
"        <p>",
"         &lt;28&deg;C",
"        </p>",
"        (&lt;82&deg;F)",
"       </td>",
"       <td>",
"        No shivering, unconscious, vital signs may or may not be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle rigidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema and edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stupor or coma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent pulses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fixed, dilated pupils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asystole",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * When present, findings are typical of the stage shown, but may vary in their presence and their temperature of onset.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_252=[""].join("\n");
var outline_f0_15_252=null;
var title_f0_15_253="Radiologic Ddx IIP";
var content_f0_15_253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiologic features and differential diagnosis of idiopathic interstitial pneumonias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histologic pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical distribution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical CT findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Differential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IPF/CFA",
"       </td>",
"       <td>",
"        UIP",
"       </td>",
"       <td>",
"        Basal-predominant reticular abnormality with volume loss",
"       </td>",
"       <td>",
"        Peripheral, subpleural, basal",
"       </td>",
"       <td>",
"        Reticular, honeycombing, traction bronchiectasis/bronchiolectasis; architectural distortion. Focal ground glass",
"       </td>",
"       <td>",
"        Asbestosis, collagen vascular disease, hypersensitivity pneumonitis, sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSIP",
"       </td>",
"       <td>",
"        NSIP",
"       </td>",
"       <td>",
"        Ground glass and reticular opacity",
"       </td>",
"       <td>",
"        Peripheral, subpleural, basal, symmetric",
"       </td>",
"       <td>",
"        Ground glass attenuation, irregular lines, consolidation",
"       </td>",
"       <td>",
"        UIP, DIP, COP, hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        COP",
"       </td>",
"       <td>",
"        OP",
"       </td>",
"       <td>",
"        Patchy bilateral consolidation",
"       </td>",
"       <td>",
"        Subpleural/peribronchial",
"       </td>",
"       <td>",
"        Patchy consolidation and/or nodules",
"       </td>",
"       <td>",
"        Infection, vasculitis, sarcoidosis, alveolar carcinoma, lymphoma, eosinophilic pneumonia, NSIP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIP",
"       </td>",
"       <td>",
"        DAD",
"       </td>",
"       <td>",
"        Progressive diffuse ground glass density/consolidation",
"       </td>",
"       <td>",
"        Diffuse",
"       </td>",
"       <td>",
"        Consolidation and ground glass opacity, often with lobular sparing. Traction bronchiectasis later",
"       </td>",
"       <td>",
"        Hydrostatic edema, pneumonia, acute eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DIP",
"       </td>",
"       <td>",
"        DIP",
"       </td>",
"       <td>",
"        Ground glass opacity",
"       </td>",
"       <td>",
"        Lower zone, peripheral predominance in most",
"       </td>",
"       <td>",
"        Ground glass attenuation, reticular lines",
"       </td>",
"       <td>",
"        RB-ILD, hypersensitivity pneumonitis, sarcoidosis, PCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RB-ILD",
"       </td>",
"       <td>",
"        RB",
"       </td>",
"       <td>",
"        Bronchial wall thickening; ground glass opacity",
"       </td>",
"       <td>",
"        Diffuse",
"       </td>",
"       <td>",
"        Bronchial wall thickening, cenrilobular nodules, patchy ground glass opacity",
"       </td>",
"       <td>",
"        DIP, NSIP, Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LIP",
"       </td>",
"       <td>",
"        LIP",
"       </td>",
"       <td>",
"        Reticular opacities, nodules",
"       </td>",
"       <td>",
"        Diffuse",
"       </td>",
"       <td>",
"        Centrilobular nodules, ground glass attenuation, septal and bronchovascular thickening, thin-walled cysts",
"       </td>",
"       <td>",
"        Sarcoidosis, lymphangitic carcinoma, Langerhans' cell histiocytosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AIP: acute interstitial pneumonia; CFA: cryptogenic fibrosing alveolitis; COP: cryptogenic OP (also called idiopathic bronchiolitis obliterans organizing pneumonia [BOOP]); DAD: diffuse alveolar damage; DIP: desquamative interstitial pneumonia; IPF: idiopathic pulmonary fibrosis; LIP: lymphoid interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; OP: organizing pneumonia; PCP: Pneumocystis jirovecii (carinii) pneumonia; RB-ILD: respiratory bronchiolitis-associated intersitial lung disease: UIP: usual interstitial pneumonia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_253=[""].join("\n");
var outline_f0_15_253=null;
var title_f0_15_254="Algorithm for cell free fetal DNA testing for fetal Rh status";
var content_f0_15_254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Algorithm for determining the results of cell-free fetal DNA testing to determine the fetal RHD status",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 371px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SNP: single-nucleotide polymorphism;",
"     <em>",
"      RHD",
"     </em>",
"     : Rhesus D gene.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: A systematic review. Obstet Gynecol 2012; 120:1132. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_254=[""].join("\n");
var outline_f0_15_254=null;
var title_f0_15_255="Map of the MHC";
var content_f0_15_255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Map of the major histocompatibility complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 469px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left portion represents the entire MHC region on chromosome 6, with the Class I, II, and III regions designated. The right portion is an enlargement of the Class II region and includes pseudogenes, other genes involved in immune function, and genes of unrelated or unknown function, as well as the \"classical\" Class II genes. The expressed \"classical\" Class II dimers are noted on the far right in bold letters (DR, DQ, and DP), and the genes encoding them are connected with dotted lines. Two different DR dimers are expressed, each sharing the same DR alpha chain (DRA), but using different DR beta chains (DRB1 and DRB3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_15_255=[""].join("\n");
var outline_f0_15_255=null;
